Mechanisms, Diagnosis and Treatment of Bone Metastases

Jozef Ban 1,†, Valerie Fock 1,†, Dave N. T. Aryee 1,2 and Heinrich Kovar 1,2,*  

1 St. Anna Children’s Cancer Research Institute, 1090 Vienna, Austria; jozef.ban@ccri.at (J.B.); valerie.fock@ccri.at (V.F.); dave.aryee@ccri.at (D.N.T.A.)  
2 Department of Pediatrics, Medical University Vienna, 1090 Vienna, Austria  
* Correspondence: heinrich.kovar@ccri.at  
† These authors contributed equally.

Abstract: Bone and bone marrow are among the most frequent metastatic sites of cancer. The occurrence of bone metastasis is frequently associated with a dismal disease outcome. The prevention and therapy of bone metastases is a priority in the treatment of cancer patients. However, current therapeutic options for patients with bone metastatic disease are limited in efficacy and associated with increased morbidity. Therefore, most current therapies are mainly palliative in nature. A better understanding of the underlying molecular pathways of the bone metastatic process is warranted to develop novel, well-tolerated and more successful treatments for a significant improvement of patients’ quality of life and disease outcome. In this review, we provide comparative mechanistic insights into the bone metastatic process of various solid tumors, including pediatric cancers. We also highlight current and innovative approaches to biologically targeted therapy and immunotherapy. In particular, we discuss the role of the bone marrow microenvironment in the attraction, homing, dormancy and outgrowth of metastatic tumor cells and the ensuing therapeutic implications. Multiple signaling pathways have been described to contribute to metastatic spread to the bone of specific cancer entities, with most knowledge derived from the study of breast and prostate cancer. However, it is likely that similar mechanisms are involved in different types of cancer, including multiple myeloma, primary bone sarcomas and neuroblastoma. The metastatic rate-limiting interaction of tumor cells with the various cellular and noncellular components of the bone-marrow niche provides attractive therapeutic targets, which are already partially exploited by novel promising immunotherapies.

Keywords: bone metastasis; metastatic niche; tumor microenvironment interactions; bone colonization; EMT; metastatic dormancy; bone reconstruction; metastasis targeted therapy

1. Introduction

Development of incurable metastasis is the cause of the majority of cancer deaths [1]. The bone is an organ frequently colonized by solid tumor metastasis [2]. Statistically, 350,000 people in the United States die each year with bone metastasis. Due to its abundant vascular supply and chemoattractiveness provided by stromal cells, osteoblasts, osteoclasts and osteocytes through production of numerous growth factors and prostaglandins, the bone microenvironment is a breeding ground for the attachment and multiplication of tumor cells [3]. Skeletal metastases are most frequently observed in multiple myeloma (up to 95%), breast and prostate cancer patients (65–80%), while lower rates are observed in patients with lung, kidney, thyroid or other cancers [4–6]. In pediatric cancers, bone metastasis is frequent in children suffering from neuroblastoma [7], osteosarcoma [8] and Ewing sarcoma [9].

The evolution of solid tumor metastasis is a complex process. Metastatic dissemination of tumor cells involves pre-metastatic niche formation, tumor cell dissemination through the circulation and chemotactic attraction and homing of tumor cells to the metastatic site of a target organ, as well as reciprocal interactions with local stromal cells and immune cells.
within the new microenvironment [10,11]. In cases involving prostate cancer metastasis to bone, as an example, it includes at least four steps: 1. colonization (circulating cancer cells enter the bone marrow niche), 2. dormancy (cancer cells adapt to the bone microenvironment and remain dormant), 3. reactivation (cancer cells switch from the dormant state to an actively proliferating state) and 4. reconstruction (cancer cells disrupt the original bone structure and function) [12,13]. These steps have been previously extensively discussed in multiple reviews [10,14,15]. Here, we aim to amalgamate the fragmented knowledge on these aspects that is available for individual cancer entities in order to highlight mechanistic communalities of the bone metastatic process for adult and pediatric solid tumors and consequences for the clinical management of this otherwise fatal condition.

The time at which potentially metastatic cells are released from the primary tumor and move to the secondary site may depend on the tumor type [16]. Several genetic studies and mutational profiling of primary and metastatic tumors suggest that additional genetic events have to occur to enable metastases formation [17]. However, dissemination of certain tumor cells, including Her2-dependent breast cancer, may occur very early, potentially already in the pre-malignant phase of the disease [18], and disseminated tumor cells can remain in a state of metastatic dormancy in colonized tissue for a long time [19]. Apparently, this process is highly ineffective as only a few tumor cells survive in the circulation and home to the metastatic site [20]. Experimental studies show that while up to 80% of tumor cells released from the primary tumor successfully pass the first steps into extravasation, only about 2–4% initiate the growth of micrometastases, and less than 0.01% survive in the new metastatic niche environment and give rise to macrometastases [21,22]. Here, tumor cells continue to evolve but are no longer dependent on the primary tumor. Early divergence from the primary tumor and acquisition of new genetic changes often result in significantly different mutation patterns compared to the predominant clones constituting the primary tumor. This last phase leading to the development of metastasis is very critical and even though there may be a large number of tumor cells in the patient’s blood and tissues, only very few of them manage to establish macrometastasis consistent with the results of experimental studies [23].

For patients, the occurrence of bone metastases is an unfavorable prognostic factor. It worsens their quality of life and increases morbidity and mortality [24–26]. In the most common bone metastatic tumors—multiple myeloma, breast and prostate cancer—the expected survival of patients after diagnosis of bone metastases is no longer than two to three years [24]. In part, this is due to bone metastases leading to skeletal morbidity, also referred to as skeletal-related events (SRE), which typically reduce overall survival. Skeletal morbidity is most common in the context of osteolytic bone metastases, which cause pathological fractures, compression of the spinal cord and spinal nerves, pain or neurological deficits, as well as hypercalcemia. In addition, a recent study demonstrated that the bone microenvironment invigorates metastatic seeds for further dissemination by enhancer of zeste homolog 2 (EZH2)-mediated epigenetic reprogramming that confers stem cell-like properties on cancer cells disseminated from bone lesions, thus further negatively impacting patient survival [27].

The main compartment affected by bone metastasis is the red bone marrow, found mainly in the central skeleton, such as the pelvis, sternum, cranium, ribs, vertebrae and scapulae, and to a variable extent in the proximal ends of long bones such as the femur and humerus. Its rich vascularization and unique cellular makeup support the homing of circulating tumor cells and the development of secondary deposits in the bone. Metastases therefore occur predominantly in the axial skeleton (>80% of patients with bone metastases), of which the majority affects the thoracic spine (70%), the lumbosacral region (20%) and cervical vertebrae (10%). Metastases to the pelvic bones, ribs and skull are found in 63, 77 and 35% of cases, respectively. The proximal long bones (humeri and femurs) are more frequently affected (53%) than the distal appendicular skeleton (1%) [10].
2. Mechanisms of Metastasis

2.1. EMT—The First Step towards Formation of Metastasis

Epithelial-to-mesenchymal transition (EMT) is a phenotypic conversion that occurs during embryonic development and tissue remodeling, where epithelial cells obtain mesenchymal-like properties in combination with reduced intercellular adhesion and enhanced motility [28,29]. EMT is a transient and dynamic process that primarily emerges at the onset of tissue invasion. It is tightly controlled by several cellular signaling pathways including epidermal growth factor receptor family tyrosine kinases (ErbB), wingless/integrated (WNT), nuclear factor kappa B (NF-κB) and transforming growth factor (TGF)-β pathways (Figure 1) [30]. The same molecular players are involved in pathological EMT during invasion and metastasis of solid tumors [31].

Figure 1. Tumor–microenvironment interactions in bone metastasis. The bone metastatic process involves several steps, including epithelial-to-mesenchymal transition (EMT), colonization of the metastatic niche, tumor dormancy, immune evasion/osteomimicry, bone reconstruction and progression to overt metastases. At later stages, tumor cells secrete factors that stimulate osteoclasts or osteoblasts, leading to excessive bone loss (osteolysis) or bone formation (osteosclerosis), respectively. Most solid tumor metastases to bone exhibit a mixed phenotype of osteolytic and osteoblastic lesions. Highlighted are several key factors that are released by tumor cells and various cell types of the bone metastatic niche mutually controlling their metastasis-driving activities. Created with BioRender.com (accessed on 27 August 2021).

EMT at the basis of metastatic cancer progression is best exemplified by metastatic breast cancer [30]. Breast cancer cell lines with increased in vitro invasiveness and in vivo metastatic potential upregulate the mesenchymal intermediate filament protein vimentin (VIM) [32], reduce cytokeratin levels and components of various cell:cell adhesion complexes such as desmoplakin (DSP), zonula occludens (ZO)-1 and E-cadherin (CDH1), with concomitant reciprocal upregulation of N-cadherin (CDH2) [33–36]. Thus, CDH2 and VIM are both bona fide markers of breast cancer EMT. Similarly in prostate cancer, markers of a mesenchymal phenotype including CDH2, osteoblast-cadherin (CDH11), and WAP-type four disulfide core/pS20 (WFDC-1) proteins are upregulated correlating with cellular motility, Skp1-cullin 1-F-box (SCF) E3 ligase complex/ubiquitin/proteasome pathway activity and loss of typical prostatic glandular architecture [37–41]. Various factors, such as hepatocyte growth factor (HGF) and epidermal growth factor (EGF) that are altered in...
the prostate cancer microenvironment through increased production by tumor cells or the cancer-associated stroma are candidates for eliciting EMT [42,43]. The impact of EGF is mediated by caveolae-dependent endocytosis and subsequent transcriptional downregulation of CDH1 by SNAI1. The transcription factor TWIST similarly represses CDH1 expression and upregulates CDH2 in prostate cancer cell lines [44,45]. In contrast, loss of prostate-derived epithelial factor (PDEF), an epithelium-specific ETS transcription factor which is downregulated by TGF-β, induces EMT in PC3 prostate cancer cells [46] as does overexpression of prostate-specific antigen (PSA) and kallikrein-related peptidase 4 (KLK4), both activators of pro-EGF and latent TGF-β2 [47,48]. While PSA and KLK4 are part of normal prostatic secretions, they leak into the tumor microenvironment due to the disruption of the glandular architecture during cancer progression, suggesting a link between tissue architecture and EMT. Further emphasizing the relationship between tumor dedifferentiation and EMT, the hedgehog and bone morphogenic protein (BMP)-7 developmental signaling pathways are reactivated in aggressive prostate cancer and can induce EMT [49]. Of note, BMP-7 is also abundant in the bone microenvironment, potentially contributing to the bone metastatic niche of prostate cancer, as it was shown that prostate cancer cells undergo EMT when experimentally inoculated into mouse bone [50].

2.2. Formation of a Pre-Metastatic Niche and Bone Colonization

Current views on tissue tropism of metastasis are based upon specific properties of the metastatic niche. The “seed and soil” hypothesis, articulated by Stephen Paget more than 100 years ago, assumes that a particular tumor cell can settle and begin to proliferate only within a compatible microenvironment [51]. Alternatively, the mechanical hypothesis suggests homing of metastatic tumor cells to be driven by physical capture in tissue capillaries of optimal diameter and blood flow to allow for extravasation at the site of metastasis. With its architecture, bone marrow is an ideal place for such an event. Its sinusoid-shaped capillaries with different throughput, wide gaps between endothelial cells and a thin connective envelope are easily permeable to tumor cells [52,53]. Slow blood flow in the red bone marrow could support the attachment of metastatic tumor cells to the endosteal bone surface. However, the molecular properties of malignant cells (seed) and their reciprocal interactions with the bone microenvironment (soil) are of greater importance in enabling the metastatic spread of the tumor [10,54]. In fact, increasing evidence suggests that primary tumors can prepare the microenvironment of a target organ to create a supportive, pre-metastatic niche for subsequent tumor cell colonization [55]. In this context, it has been shown that cancer-associated fibroblasts (CAFs) in the tumor stroma can prime tumor cells for dissemination to the bone via secretion of C-X-C motif chemokine ligand 12 (CXCL12, also known as SDF-1) [56] (Figure 1). Well in line, overexpression of CXCL12 receptors (CXCR4 and CXCR7) by breast and prostate cancer cells induces chemotaxis along CXCL12 gradients to allow for colonization of the bone [57–60]. Importantly, high expression of CXCR4 in breast cancer has been associated with a higher incidence of distant metastasis and bone metastasis as compared to low CXCR4 expression [61]. Annexin A2 (ANXA2)/annexin A2 receptor (ANXA2R) interactions between osteoblasts or endothelial cells and circulating prostate cancer cells have also been reported to support homing and adhesion to bone [62,63]. Receptor activator of NF-κB (RANK) expression by prostate cancer cells promotes pre-metastatic niche formation by activating a RANK-L/c-Met-mediated feedforward loop, thus inducing cancer cell colonization to the bone [64]. Tumor-derived proteolytic enzymes such as matrix metalloproteinases (MMPs) can remodel the bone matrix to release and activate growth factors and cytokines, which create a favorable environment for metastatic colonization [65–67] (Figure 1). Secretion of lysyl oxidase (LOX) by primary breast cancer cells under hypoxic conditions has been shown to modulate the ECM at bone metastatic sites to create a pre-metastatic niche [68]. Additionally, exosomes and microRNAs produced by the primary tumor cells have been associated with bone remodeling and the development of metastasis in the bone [69,70]. Adhesion molecules such as integrin αvβ3, the receptor for vitronectin, can facilitate the anchorage of disseminating cancer cells
to the extracellular matrix (ECM) of the bone niche [71,72]. Furthermore, osteoblast-derived Wnt-induced secreted protein-1 (WISP-1) has been implicated in regulating the adhesion of prostate cancer cells to osteoblasts via VCAM-1/integrin α4β1 (also known as very late antigen-4, VLA-4) [73]. Another study has shown that bone marrow-derived interleukin (IL)-1β promotes metastatic colonization of disseminated breast cancer cells in the bone by stimulating the NF-κB/CREB-Wnt pathway [74]. Finally, binding of metastatic breast cancer cells to E-selectin in the bone vascular niche during early metastatic colonization has been reported to induce mesenchymal-to-epithelial transition (MET), thus facilitating growth at the metastatic site [75,76].

Of note, the precise location and composition of the bone “metastatic niche” of different cancers are poorly defined. It has been proposed to comprise a hematopoietic stem cell (HSC), endosteal (osteoclasts, osteoblasts, osteocytes, fibroblasts) and vascular (endothelial cells, pericytes) niche compartment [13,77,78]. A role in breast cancer colonization of the bone has also been assigned to the adipose tissue compartment in the bone marrow [79]. These niches are considered to be quite stable without undergoing major remodeling over long periods of time, resulting in long latencies in the development of bone metastases [13]. For example, stable microvasculature can retain cancer cells in a dormant state, whereas sprouting vessels activate dormant cells and accelerate micrometastatic outgrowth [80]. Along those lines, long-term quiescent cells such as bone lining cells may thus be more likely to support long-term tumor cell dormancy as compared to bone-synthesizing osteoblasts. Interestingly, human prostate cancer cells have been shown to directly compete with HSCs for occupancy of the endosteal niche during bone marrow transplantation in mice [81]. Most importantly, treatment of mice with HSC-mobilizing agents, such as the CXCR4 antagonist AMD3100 or G-CSF, also resulted in the egression of prostate cancer cells from the bone marrow into the peripheral blood. It therefore seems conceivable that disseminating cancer cells in the bone marrow are subject to similar homing, survival and dormancy mechanisms as HSCs. Breast cancer cells, once nested to bone, undergo partial osteomimicry by acquisition of typical bone cell markers including ICAM-1, CDH11, OPN, osteonectin (SPARC), osteocalcin (BGLAP) and cellular communication network factor 3 (CCN3). This in turn promotes osteoclast-mediated bone resorption through the production of RANK-L, IL-2β, IL-6, IL-11 and tumor necrosis factor (TNF)-α, and supports evasion of an immune response [82–84] (Figure 1). Besides breast cancer, osteomimicry has been observed across various bone metastatic cancers including prostate cancer and osteosarcoma [85].

2.3. Metastatic Dormancy and Reactivation in the Bone Niche

Solitary disseminated primary tumor cells, once settled in the bone niche, may grow immediately or adopt a nonproliferating dormant state remaining quiescent in the bone marrow for up to decades (“cellular dormancy”) [78,86,87]. A comprehensive mechanistic insight into tumor dormancy, including its implications in tumor invasion and metastasis, has recently been provided [88]. For bone metastases, the fate of colonizing tumor cells most likely depends on their specific location in the bone microenvironment, where around 20% of the endosteal surface undergoes active remodeling, whereas the other 80% remains relatively quiescent at any given time [13]. While actively remodeled surfaces will provide factors that support tumor growth and survival, quiescent compartments of the bone will rather promote dormancy. In the bone microenvironment, both BMP-7 and TGF-β2 have been shown to maintain tumor cell dormancy via reduced focal adhesion kinase (FAK)/EGFR signaling and a high p38 mitogen-activated protein kinase (MAPK) over extracellular signal-regulated kinase (ERK) ratio, favoring cell cycle arrest and inducing a dormant state [89,90].

Specific ligand/receptor interactions with osteoblasts in the bone marrow niche appear to play a major role for the induction of cancer cell dormancy [86,91] (Figure 1). For example, ligand growth arrest-specific 6 protein (GAS6)/AXL interaction with osteoblasts retains bone-metastatic prostate cancer cells in a dormant state [92–94]. Interestingly,
prostate cancer cells express a repertoire of GAS6 receptors (including AXL, MER and TYRO3), a balanced expression of which has been shown to control dormancy (AXL) or proliferation (TYRO3) [95]. AXL expression is stabilized by hypoxia [96] and hypoxic regions in the bone are less prone to metastasis development [97]. Furthermore, osteoblast-derived growth differentiation factor 10 (GDF10) and TGF-β2 have been reported to induce prostate cancer cell dormancy via activation of TGFBR3–p38 MAPK signaling [98]. Additionally, the WNT5a/receptor tyrosine kinase-like orphan receptor (ROR)-2/Seven in the absentia homolog (SIAH)-2 signaling axis plays a crucial role in inducing and maintaining prostate cancer cell dormancy in the bone [99]. Besides the osteoblast lineage, also other cell populations, such as mesenchymal stem/stromal cells and endothelial cells, have been implicated to play a role in modulating cancer cell dormancy (Figure 1). As such, MSC-derived exosomes have been shown to maintain dormancy of metastatic breast cancer cells and hence to decrease their sensitivity to chemotherapy [100]. Interestingly, breast cancer cells can actually prime MSCs to release microRNA-containing exosomes to promote quiescence [101]. Additionally, secretion of thrombospondin (TSP)-1 from endothelial cells in the perivascular niche can induce dormancy of breast cancer cells [80].

Recently, it has been demonstrated that a subset of periarteriolar MSCs with a neuronal glial antigen 2 (NG2)+, Nestin+ phenotype produce TGF-β2 and BMP-7 to activate a quiescence pathway in metastatic breast cancer cells by inducing cyclin-dependent kinase inhibitor 1B (CDKN1B) via MAPK activation [102].

Dormant cancer cell reactivation in the bone niche can be influenced by cell-intrinsic changes in gene expression programs in response to various extrinsic cues, including remodeling of the metastatic niche where dormant cancer cells reside, and secretion of tumor-promoting signals [86,87,103,104]. For example, it has been demonstrated that myeloma cells are released from dormancy via RANK-L-driven osteoclastic bone resorption [105]. Accordingly, induction of bone resorption via ovariectomy or castration in mice has been reported to increase the formation of breast and prostate cancer metastases, a process which can be blocked by osteoclast inhibition [20,106,107]. Aberrant VCAM-1 expression by metastatic breast cancer cells has been shown to recruit integrin α4β1+ osteoclast precursors, initiating tumor cell reactivation through bone resorption [108]. It seems likely that the frequency of metastases is determined by the number of dormant cells colonizing the endosteal niche as well as the rate of osteoclastic bone resorption, with a higher rate enhancing the chances of dormant tumor cell reactivation. Interestingly, besides their dormancy-promoting function, there is also increasing evidence that osteoblasts contribute to the reactivation of dormant cancer cells in the bone niche (Figure 1). For example, decreased TGF-β and GAS6 expression by osteoblasts can release dormant prostate cancer cells from dormancy [92]. Similarly, reduced secretion of BMP-7 by osteoblasts and MSCs resulted in enhanced prostate cancer cell proliferation in vitro and in vivo [89]. Of note, direct interactions with osteoblasts and cells of the osteogenic niche have been reported to shorten the period of breast cancer cell latency and induce tumor growth in the bone. In particular, heterotypic adherens junctions between breast cancer cell-derived CDH1 and CDH2 in an osteogenic niche can support bone colonization of circulating breast cancer cells and stimulate the mechanistic target of rapamycin (mTOR) pathway-driven micrometastasis formation [109]. Additionally, physical changes in the perivascular niche, such as angiogenic sprouting, can remove suppressive signals (e.g., TSP-1), thus releasing cells from dormancy and triggering cancer cell growth [80]. For example, periostin and TGF-β released from endothelial tip cells of the neovasculature have been shown to promote rapid tumor growth in mice [80].

Upon reawakening, tumor cells undergo MET and start to proliferate. The energy required for growth in the bone niche is at least partly provided by bone marrow-resident adipocytes that release free fatty acids to fuel tumor cell proliferation. They also release leptin (LEP), which stimulates further adipocyte generation from bone marrow MSCs. In addition, LEP has been demonstrated to be involved in tumor cell attraction to the bone
marrow niche and to enhance proliferation and migration of tumor cells, while adiponectin from bone marrow adipocytes most likely contributes to tumor dormancy [110] (Figure 1).

2.4. Reconstruction: Osteoblastic versus Osteolytic Bone Metastases

Under normal physiological conditions, osteoblast- and osteoclast-mediated bone remodeling is tightly coordinated in time and space, and bone deposition and bone resorption are in balance. However, this balance is disrupted in bone metastatic cancers [104]. Depending on the cancer type, metastatic tumor cell growth in the bone niche either leads to increased production of molecules that disrupt bone homeostasis stimulating osteolysis by osteoclasts, or it causes osteosclerosis through stimulation of osteoblast activity. Although the vast majority of bone metastases of solid tumors present both osteolytic and osteoblastic components, one or the other phenotype prevails in specific bone metastatic cancers.

As an example, the majority of bone metastatic lesions in breast cancer patients is osteolytic [111–113]. The process by which breast cancer cells metastasize to the bone is frequently referred to as a “vicious cycle” [114]. It begins when metastatic breast cancer cells produce parathyroid hormone-releasing peptide (PTHrP), which binds to the same receptors as parathyroid hormone and stimulates osteoblasts to secrete increased amounts of RANK-L. The interaction between RANK-L and its receptor RANK on osteoclast precursors stimulates osteoclastogenesis and thus bone resorption. This in turn leads to the release and activation of growth factors such as insulin-like growth factor (IGF)-1, and TGF-β from the bone matrix, which induces cancer cells to proliferate and to produce additional PTHrP (Figure 1). Constitutive osteoclast activation results in sustained osteolysis to provide space for the development of metastatic lesions. Bone degradation also leads to the release of calcium, which further supports the growth of tumor cells expressing extracellular calcium-sensing receptors [115,116]. A variety of tumor-derived factors significantly contribute to the formation of breast cancer metastases in bone, including IL-11, plasminogen activator (PLAU), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), BMPs and TGF-β [117–121]. Additionally, bone-derived placental growth factor (PGF) is upregulated in the presence of breast cancer cells, resulting in a decreased production of the RANK-L binding glycoprotein osteoprotegerin (OPG) from osteoblasts and stromal cells, thus stimulating the formation of osteolytic lesions due to increased RANK-L levels, which can be prevented by PGF blockade [122] (Figure 1).

Importantly, the vicious cycle model does not take into account the part that dormant cells play in tumor development or the events that initiate the interdependence between tumor cells and osteoclasts. As an alternative to this model, it has been suggested that osteoclasts may not only be bystanders that respond to tumor-derived factors, but rather be responsible for initiating the vicious cycle by first remodeling the endosteal niche, thereby releasing dormant cancer cells from niche-dependent control and reactivating them to form micrometastases [13]. In agreement with this hypothesis, stimulators of osteoclastic bone resorption (e.g., PTHrP overexpression, vitamin D deficiency or calcium restriction) can promote bone metastasis [114,123–125], whereas inhibitors of bone resorption such as OPG treatment or bisphosphonates slow down tumor growth in the bone [126–128]. Besides their role in the reactivation of dormant tumor cells, osteoclasts may also be involved in fueling the second part of the vicious cycle, when the tumor is already established and starts modifying the microenvironment.

Skeletal metastasis in multiple myeloma predominantly results in osteolytic lesions due to the inhibition of osteoblastic differentiation, reduction in bone deposition and increased osteoclast activity triggered by a variety of osteoclast-activating and osteoblast-inhibitory factors produced by both tumor and stromal cells. These include osteoclast activators macrophage inflammatory protein (MIP)-1α, RANK-L, vascular endothelial growth factor (VEGF), TNF-α, IL-1β, PTHrP, HGF and IL-6. In addition, amphiregulin (AREG) in multiple myeloma-derived exosomes leads to the activation of EGFR in pre-osteoclasts, participating in osteoclastogenesis [129]. Osteoblast inhibition is mediated via direct downregulation of VLA-4/VCAM-1-mediated Runt-related transcription factor
of IL-7 as well as the WNT-signaling antagonist dickkopf-1 (DKK-1) [130,131] (Figure 1).

In contrast to bone metastatic breast cancer and multiple myeloma, bone metastatic prostate cancer forms lesions, which are predominantly osteoblastic [132]. This is due to prostate cancer cells preferentially homing to osteoblastic regions of the bone [133]. Unique and direct interactions between bone metastatic prostate cancer cells and osteoblasts provide growth-promoting effects to both cell types (Figure 1). For example, prostate cancer cells secrete BMPs, TGF-β, IGF-1, PDGF, endothelin-1 (ET-1), VEGF and microRNA (miR)-940, which promote osteoblast differentiation and activation [134–137]. This confers a dramatic disruptive effect on the formation of an organized bone structure as well as the collagen matrix, resulting in a bone with a disordered spongy structure compared to a compact lamellar architecture. Activated osteoblasts also produce factors that trigger prostate cancer cell proliferation (e.g., VEGF, C-C motif chemokine ligand CCL2, IL-6 and IL-8) [138]. Furthermore, secretion of ET-1 by prostate cancer cells has been shown to suppress DKK-1, activating Wnt signaling and osteoblast-mediated bone deposition [139]. Prostate cancer growth is further enhanced by activated osteoclasts, which release growth factors from the resorbed bone matrix [140]. Prostate cancer-derived exosomes also contribute to extensive osteoblastic lesions delivering ETS1 [141], miR-940 [142] and miR-141-3p [143] to the stroma within the metastatic bone niche. Various survival pathways have been reported to participate in prostate cancer growth in the bone niche, including PThrP, TGF-β, IGF-1, FGF-2, IL-6 as well as ET-1 signaling [20,144].

Rare osteoblastic and mixed osteoblastic/osteolytic bone lesions can be observed in a fraction of breast cancer patients. These are promoted by communication of tumor cells with osteoblasts and osteoclasts through interaction of variably expressed PDGF and ET-1 with their respective receptors PDGFRα/β and ETAR on osteoblasts and osteoclasts [145–147]. Their expression levels determine the development of different types of lesions. In addition, the β-catenin signaling pathway has a significant impact on the bone lesion phenotype and acts as an important determinant in mixed osteoblastic and osteolytic lesions [148]. It was demonstrated that human breast cancer cell lines that preferentially form osteolytic bone metastases exhibited increased levels of Wnt/β-catenin signaling and DKK-1 expression, which blocked WntβA-induced osteoblastic differentiation [149].

2.5. Bone Microenvironment and Bone Sarcomas

The bone microenvironment is also a fertile soil for the metastasis of the most frequent primary bone sarcomas, osteosarcoma and Ewing sarcoma. Therefore, metastatic bone sarcoma cells can enter, colonize and expand in it, exploiting very similar mechanisms as described above for epithelial cancers and multiple myeloma.

Osteosarcoma is assumed to originate from the bone mesenchymal lineage. Transforming genetic (e.g., TP53, RB or CDKN2A deficiency, aneuploidization), as well as epigenetic aberrations in osteoblast progenitor cells lead to the production of malignant osteoid and immature bone tissue [150–152]. In addition, osteosarcoma cells attract normal bone marrow MSCs to the tumor stroma via secretion of CCL2, CXCL1 and TGF-β, supporting their trans-differentiation into cancer-associated fibroblasts (CAFs). As a consequence, CCL2, CXCL1, IL-6 and IL-8 levels are further increased in the tumor microenvironment, eliciting mesenchymal to amoeboid transition of osteosarcoma cells through activation of Ras homology family member A (RHOA) signaling, which promotes motility, invasiveness and trans-endothelial tumor cell migration [153]. Disseminated osteosarcoma cells can resist anoikis (detachment-induced cell death) by expressing fatty acid synthase and potentially related molecules including p-ERK1/2 and BCL-xL [154]. In addition, MSCs support osteosarcoma invasion and metastasis by secreting extracellular vesicles as carriers to transport metastasis-promoting microRNAs (e.g., miRNA-21 and -34a), proteins (e.g., PDGFR-β, tissue inhibitor of metalloproteinases TIMP-1 and TIMP-2), bioactive lipids such as sphingomyelin and metabolites, including glutamic and lactic acids, to the tumor cells [155]. The balance between normal bone formation and bone resorption
depends on the acidity of the bone microenvironment. Hypoxia and interstitial acidosis are also important in the promotion of osteosarcoma bone metastasis, in part through activation of IL-8, IL-6, NF-κB, colony-stimulating factors CSF2 and CSF3, BMP-2, CCL5, CXCL5 and CXCL11 in tumor-associated MSCs [156] (Figure 1). Hypoxia also directly affects migration and invasion of the metastatic tumor cells through induction of hypoxia-inducible factor (HIF)-1α, which is under the control of several factors in osteosarcoma cells including TGF-β1 [157,158], miRNA-20b [159] and miRNA-33b [160]. Besides pH, phosphatidylinositol-3-kinase (PI3K)/Akt is one of the most important signaling nodes that regulates cell motility, adhesion, growth and metastasis of osteosarcoma cells [161,162]. It interacts with MAPK/ERK [163,164], Hedgehog [165,166] and Wnt pathways [167]. Wnt/β-catenin signaling increases the expression of RUNX2 to facilitate metastasis-related gene expression, thus supporting osteosarcoma cell invasion [168–170]. Specifically, BMP-2 mediated β-catenin activation and the RhoC/Rho-associated kinase ROCK1/MAPK/Twist1 signaling pathway enhance osteosarcoma growth and promote EMT [171].

In Ewing sarcoma, the pathognomonic driver oncogene EWS-FLI1 modulates several biological pathways including IGF-1, PDGF, VEGF, Wnt and TGF-β signaling, which results in differentiation arrest, proliferation, angiogenesis and immune escape of tumor cells [172]. On the other hand, fluctuations in EWS-FLI1 activity levels promote Ewing sarcoma EMT and increase its metastatic potential [173–175]. These may either be due to modulations in the expression of the chimeric protein [175], or the result of perturbations in 3D extracellular matrix organization at EWS-FLI1 binding regions caused by the loss of the cohesion component STAG2 [176,177]. Experimental modulation of EWS-FLI1 upregulates the activity of several key players in EMT, including master regulators SNAI1/SNAI2 and ZEB1, mechanosensitive transcriptional cofactors YAP/TAZ [178] and the NOTCH effector protein and transcriptional repressor Hairy/enhancer-of-split related with YRPW motif 1 (HEY1) [179]. Upon entering the circulation, Ewing sarcoma cells overcome anoikis by upregulating IL-1 receptor accessory protein (IL1RAP) enabling metastatic spread [180]. Upon homing to bone, Ewing sarcoma cells produce osteoclast-activating factors, such as IL-1 [181] or TNF-α [182], which induce osteoclast differentiation and activation and thus lead to extensive osteolysis. Additionally, EWS-FLI1 and EZH2, whose mRNAs have been shown to be shed from the tumor cells as an exosome cargo [183,184], may not only bind and block RUNX2 in the tumor cells [185] but also prohibit osteoblast differentiation of mesenchymal cells in the tumor stroma, thus shifting the homeostatic balance in the metastatic bone niche to osteoclast activation. On the other side, when osteoclasts resorb bone, they allow the release of growth factors stored in the bone matrix (IGF-1, TGF-β, PDGF, etc.), which in turn can activate tumor cell proliferation in a vicious cycle [186]. This scenario still needs to be confirmed for metastatic Ewing sarcoma [187].

2.6. Bone Metastases in Extraosseous Pediatric Solid Tumors

Among pediatric malignant soft tissue tumors, bone/bone marrow metastasis is rare in rhabdomyosarcoma and retinoblastoma [188,189]. In contrast, the bone marrow is the primary site of metastasis in neuroblastoma, the most common extracranial solid tumor in children. The best-characterized adverse prognostic factor associated with neuroblastoma progression is amplification of the MYCN oncogene, which dysregulates protein kinase C (PKC) leading to constitutive phosphorylation of a number of growth factor receptors, and downregulation of CDH2 affecting cell adhesion [190,191]. The combination of MYCN overexpression with caspase-8 depletion, which is frequently observed in human neuroblastoma due to epigenetic silencing, induced the expression of genes involved in EMT and inflammation, and downregulated miR-7a and miR-29b, significantly enhancing bone marrow metastasis in a neuroblastoma mouse model [192]. Overexpression of tropomyosin receptor kinase B (TRKB), the receptor for bone-derived neurotrophic factor, in neuroblastoma cells is associated with increased bone marrow invasion through upregulation of several MMPs (e.g., MMP-1, MMP-2, MMP-3, MMP-9), as well as of serine proteases urokinase and tissue plasminogen activators (PLAU) which degrade the
ECM [193] (Figure 1). Co-expression of CXCR4, specifically the 47kD isoform, and CXCR7 significantly and selectively increased neuroblastoma dissemination toward the bone marrow [194]. Bradykinin and ATP leaking from inflammatory processes or damaged cells promoted the attraction of neuroblastoma cells to the bone marrow through stimulating chemokine CXCL12/CXCR4/CXCR7 interactions [195]. Furthermore, CXCRI/CXCL13 and CXCR1/CXCL1 interactions may specifically contribute to neuroblastoma bone marrow metastasis in part by facilitating transmigration of neuroblastoma cells through the bone marrow endothelium [196,197]. Bone marrow infiltration is further supported by IL-6 provided by MSCs upon Galectin-3 stimulation produced from neuroblastoma cells [198]. In turn, the secretome of bone marrow MSCs was shown to promote the expression of the 47 kDa CXCR4 isoform and also increased MMP-9 secretion, expression of integrin α3 and integrin β1, supporting the invasive potential of neuroblastoma cells [199]. A recent study revealed that metastatic neuroblastoma cells alter the frequency and functionality of bone marrow stroma cells, increasing their differentiation capacity towards the osteoblastic lineage, partially mediated by miR-375 shed from the tumor cells in exosomes [200]. In particular, a novel tumor-specific subpopulation of CD146+CD271− MSCs characterizes the bone marrow of metastatic neuroblastoma patients [201]. In addition, bone marrow infiltration by neuroblastoma cells increases CD203a and CD73 expression on lymphoid and myeloid cells [202] and derived microvesicles. CD203a—an ectonucleotide-pyrophosphatase-phosphodiesterase—and CD73 catalyze the final steps of immunosuppressive adenosine generation from nicotinamide adenine dinucleotide resulting in inhibition of T-cell proliferation and immune escape [202]. Finally, analysis of neuroblastoma cells isolated from the bone marrow of patients with metastatic disease by immunomagnetic enrichment using anti-GD2 monoclonal antibody identified adaptation to the microenvironment by downmodulation of chemokine (C-X3-C motif) ligand 1 (CX3CL1), angiotensinogen (AGT), Na+/K+-ATPase alpha 2 (ATP1A2) and upregulation of several genes commonly expressed by various lineages of bone marrow resident cells, such as S100A8 and A9 (calprotectin), CD177, CD3 and CXCL7. Bone marrow-infiltrating neuroblastoma cells also expressed CD271 and human leukocyte antigen (HLA)-G [203]. Together, these data exemplify the mutual reprogramming of the host microenvironment and the infiltrating tumor cells in bone/bone marrow metastasis.

3. Diagnosis and Therapy of Bone Metastases

The most common initial clinical symptom of bone metastasis is pain. This is because tumor cells produce substances that irritate unmyelinated C-fiber neurons including bradykinin and substance P. A number of other causes also contribute to the onset of pain, including deformation and consequently, irritation of the peristome due to small microfractures of the trabecular bone. Advanced stages of bone-metastatic growth are frequently associated with pathological fractures, mainly of the long bones (femur, humerus), which occur predominantly in the proximal parts thereof. In 5–10% of patients with metastatic spinal cord injury, metastases cause vertebral body fractures [204]. The standard-of-care imaging methods to detect bone metastases include X-ray, bone scintigraphy and computed tomography (CT), all of which assess the stromal reaction to cancer cells within the bone marrow, rather than depicting cancer foci themselves [10]. This not only limits early metastasis detection but also the assessment of the treatment response. Therefore, high sensitivity methods including whole body magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) are increasingly used to improve the detection of metastatic bone disease.

At the beginning of bone metastatic growth, the process manifests by osteopenia, detectable by X-ray examination. Pathological changes in bone metabolism and bone structure arising from increased osteoblast activity in the vicinity of metastases is monitored by bone scintigraphy, a radiotracer-based imaging method [205–207]. Due to minimal tracer uptake in purely osteolytic lesions, bone scintigraphy is not applicable for the initial diagnosis of patients with multiple myeloma [10]. CT imaging enables the assessment of
the condition of cortical and trabecular bone, and a better spatial representation of the skull, pelvis and spine. It also helps to distinguish bone metastasis from hemangioma. However, significant bone destruction or new bone formation must occur before a lesion is detectable in a CT scan [10]. The most sensitive method for assessing bone metastases in the bone marrow is MRI capturing details of 80–90% of bone marrow areas in a single scan [208]. In addition, the recently developed synthetic MRI technique allows the evaluation and quantification of bone lesions, and to discriminate viable progressive osteoblastic from nonviable bone metastases during treatment, as demonstrated for prostate cancer patients [209]. PET-CT uses various isotopes, including the bone turnover-specific tracer fluorine-18 sodium fluoride (\(^{18}\)F-NaF), as indicators of skeletal metastases and is able to distinguish them from benign lesions [210]. Compared to scintigraphy, PET-CT has a higher sensitivity and specificity, thus enabling the detection of skeletal metastases in early stages [211].

In addition to these imaging technologies, biochemical examinations play an important role in the diagnosis of patients with suspicious bone metastases as has been previously reviewed in detail [212,213]. These include bone isoenzyme of alkaline phosphatase (BALP), BGLAP, carboxy-terminal propeptide of type I procollagen (PICP), N-terminal propeptide of type I collagen (PINP), carboxy-terminal telopeptide of type I collagen (ICTP), fasting urinary pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) collagen degradation products. Serum calcium is also a standard test, and higher calcium levels are an indicator of osteolysis. Bone resorption can be the result of two distinct enzymatic activities. Cathepsin K mediates physiological bone resorption, while degradation by MMP-9 is activated in a pathological situation. ICTP specifically reflects the pathological degradation of bone tissue by MMP-9 and is therefore a highly specific marker of bone resorption caused by a metastatic process.

The therapy of patients with bone metastases is primarily a palliative treatment with the goal of alleviating pain and improving quality of life. Treatment decisions for bone metastases depend mainly on their location, the patient’s general condition and the treatment the patient has received so far. It is usually a combination of local and systemic treatments.

Surgical procedures depend on the size and number of bone metastases and are not applicable for patients with multiple metastatic lesions. During the growth of bone metastases, gradual reduction in bone mass leads to the risk of pathological fractures, mostly of long bones, or collapse of the vertebral body, and compression of the spinal cord or spinal nerves can occur. Such conditions usually require acute orthopedic or neurosurgical treatment. In the majority of cases, there are stabilization procedures for impending pathological fractures, and osteosynthesis or excocleation of a metastatic deposit with filling of the cavity with bone cement. When this is not possible, the limb or spine can be stabilized with an extension, orthosis or corset [214]. In patients with insufficient pain treatment, contra-indications of surgery or risk of progression after surgical stabilization, injection of bone cement or tissue adhesive based on polymethylmethacrylate into the affected area under sciascopic control can be performed using interventional radiology [215,216]. This technique is known as vertebroplasty in cases involving vertebral involvement, or cementoplasty in cases where long bones are affected. These methods provide pain relief in up to 75% of patients. Their advantage is that they do not place too much strain on the patient and can be combined with other therapeutic procedures.

External beam radiotherapy in combination with analgesics is the basic palliative treatment of advanced bone metastatic disease and is a very effective treatment for pain relief. In addition to killing tumor and inflammatory cells preventing discomfort to adjacent nerves, it promotes ossification by destruction of osteoclasts, and thus may stabilize bone. Its advantages are minor side effects, and acting directly against the cause of bone pain. For palliative radiotherapy in patients with bone metastases, the optimal dose-fractionation schedule remains a matter of debate in terms of efficacy, safety and cost-effectiveness. When classical radiotherapy is not practical, radiopharmaceuticals such as radium-223 may be
applied instead [217]. Radiopharmaceuticals incorporate into new bone and emit particles (alpha and beta) to kill nearby cancer cells [218,219]. Therefore, they preferentially accumulate in osteoblastic bone metastases, and have been shown to improve both the survival and quality of life of prostate and breast cancer patients [218]. Unfortunately, their application for treatment of osteolytic bone metastasis is limited because of myelosuppression [9].

After local therapy by surgery and/or radiotherapy, systemic neoadjuvant or adjuvant anticancer chemotherapy is applied to patients with bone metastasis. For prostate cancer patients, taxanes (docetaxel and cabazitaxel), which are mitotic inhibitors, provide the only systemic treatment option [220–222]. In cases involving breast cancer patients with bone metastases, the chemotherapeutic armamentarium contains several compounds including anthracyclins (inhibitors of DNA synthesis and RNA synthesis) [223], vinorelbine (microtubule disruptor) [224] and capecitabine (thymidylate synthase inhibitor) [225] combined with surgical resection of the primary and metastatic tumors. In the absence of any proven alternatives, chemotherapeutic treatment of osteosarcoma patients with bone metastases still follows the same approach with three agents (methotrexate, cisplatin and doxorubicin) as the treatment of the primary tumor [226]. Similarly, the standard-of-care chemotherapeutic treatment of bone metastatic Ewing sarcoma uses the same backbone regimen as first-line treatment for localized disease, and the benefit of myeloablative dose intensification followed by HSC transplantation remains controversial [227,228].

Analgesic therapy is an integral part of palliative treatment of bone metastases. It is a supportive treatment which, if properly managed, reduces tumor pain to a tolerable level and thus improves the overall condition and quality of life of the patient [229]. For neuropathic and mixed pain, it is advisable to combine analgesics with antidepressants or anticonvulsants. For severe pain, the administration of strong opioids dominates. In addition to the analgesics, corticosteroids may be used to treat pain in multiple skeletal disorders.

3.1. Approaches to Biologically Targeted Therapy

The preclinical development of targeted antimetastatic treatments requires adequate models that recapitulate the specific biology of metastases in their niche. For the study of bone metastases, conventional cell line-based or patient-derived xenografts (PDX), which largely retain gene expression patterns and clinical features of the human tumor in rodent hosts, are still considered the gold standard [230–232]. However, their use is limited as species-specific factors may prohibit homing of human tumor cells to rodent bones, and the site of tumor cell inoculation greatly impacts organ tropism. An improvement of such systems is provided by subcutaneous human bone implant models, which upon subsequent inoculation of metastatic tumor cells allow them to home to their natural human bone-niche microenvironment in the mouse [233]. Alternatively, an artificial matrix consisting of mature human osteoblasts trapped on a collagen hydroxyapatite substrate, which is then implanted subcutaneously into SCID mice, can be used to generate an easily accessible human bone microenvironment for tumor cell transplantation and anti-bone-metastatic treatment studies [234]. Despite their limitations, xenograft models have been successfully used to unravel the role of tumor-derived exosomes in the bone-metastatic process [235] of bone-derived leukemia inhibitory factor (LIF) and Wnt5 in promoting dormancy of metastatic breast and prostate cancer cells in the bone, respectively [99,236], and of factors promoting bone-metastatic growth including IL-1 in breast cancer [237], G protein-coupled receptor class C group 5 member A (GPRC5A) and NOTCH3 in prostate cancer [238,239]. Xenograft models have proven valuable in the pre-clinical anti-bone-metastatic development of bisphosphonates, the RANK-L-neutralizing monoclonal antibody denosumab, soluble RANK (RANK-Fc), osteoprotegrin-Fc (alone and in combination with docetaxel), several receptor tyrosine kinase inhibitors (dasatinib, saracatinib, and KX2-391) and the α5β3 integrin-targeting antibody etaracizumab [240].

Bisphosphonates and denosumab mechanisms of action have recently been comprehensively reviewed for the treatment of bone metastases [14]. They either directly or indirectly (via inhibition of osteoclast-activating PDGF and VEGF production) inhibit os-
teoclast activity (Figure 2). They also improve tumor response to treatment by depletion of tumor-associated macrophages that support tumor growth. According to the latest research, bisphosphonates, especially zoledronate, are not only osteoprotective, but also have antiangiogenic, immunomodulatory and antitumor effects. They improve bone metabolism, suppress the formation, growth and spread of bone metastases and have an analgesic effect [241]. While denosumab is currently being tested in combination with bisphosphonates for the treatment of bone metastases in breast and prostate cancer patients [242,243], recent phase III clinical trials adding zoledronic acid to standard backbone chemotherapy of both osteosarcoma and Ewing sarcoma failed to improve patient survival [244,245]. Although bisphosphonates and denosumab inhibit osteoclast activity and tumor-induced osteolysis, they do not restore bone formation. Given the key role of the ubiquitin–proteasome system in controlling the degradation of various bone-related proteins and the importance of regulatory ubiquitination in cancer metastasis [246,247], focus has been drawn to the potential use of proteasome inhibitors for the improvement of bone anabolism [248]. Among these, bortezomib, carfilzomib and ixazomib have shown promising results in stimulating osteoblast differentiation and bone healing through multiple mechanisms. For example, bortezomib can enhance bone formation by increasing the expression of BMP-2 in osteoblastic cells, which leads to increased RUNX2 activity and the upregulation of BGLAP, ALP and collagen I [249,250]. Bortezomib also promotes endoplasmic reticulum stress through IRE1α/XBP1 signaling, resulting in increased expression of various osteoblast markers [251,252]. In mice inoculated with breast cancer cells, bortezomib treatment was shown to reduce osteolytic lesions and to exhibit bone anabolic effects [253]. Bortezomib was further reported to prevent bone metastasis of prostate cancer cells by inhibition of the WW domain containing E3 ubiquitin protein ligase 1 (WWP1) and Smurf ligases, which are frequently upregulated in patients with bone metastasis [254]. Since proteasome inhibitors act in a nonspecific manner, their use as bone anabolic therapy is rather limited. Therefore, conjugation of bortezomib to bisphosphonates as well as the generation of bone-specific nanoparticles have been proposed to selectively deliver proteasome inhibitors to the bone and to prevent systemic side effects [255]. Furthermore, several attempts have been undertaken to specifically target BMPs, PTH or OPG in order to improve bone integrity [256]. Finally, biocompatible polymers may provide novel strategies to enhance bone healing in patients with metastatic bone cancers [257].

For large-scale antimetastatic drug-screening purposes, the use of xenograft models is limited. More recently, bone explant [258] and scalable 3D in vitro models based on organoid and 3D bioprinting technologies have moved into the focus of pre-clinical research. Although they lack vascularization, they at least partially recapitulate the physical, cellular and spatial complexity of the tissue from which they derive, and retain the genetic and functional heterogeneity of the original tumor. As an example, it was shown that organoids generated from human prostate cancer bone metastases retained the same resistance pattern to antiandrogen therapy as the patients’ metastases [259]. An ex vivo tumor/bone coculture model was used to demonstrate that the CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis [258]. In addition, the composition of the bioink used in the printing process allows inclusion of bone-specific matrix components. Using this approach, 3D-bioprinted and bone-on-a-chip models for breast cancer bone metastasis [260–262] and metastatic neuroblastoma [263] were successfully established.

Among conventional targeted therapies, hormone therapy is used for the palliative treatment of metastatic skeletal disorders in prostate and breast cancer, which depend on sex hormone signaling for growth (Figure 2). In patients with estrogen receptor-dependent breast cancer, antiestrogens (e.g., tamoxifen, fulvestrant) [264,265] and aromatase inhibitors (anastrozole, letrozole, exemestane) are used [266]. Ovariectomy or chemical castration can be performed using analogues of gonadotropin-releasing hormone (luteinizing hormone releasing hormone, LHRH), such as zoladex. In patients with prostate cancer, orchietomy or treatment with LHRH analogues are primarily performed. If this treatment fails, antiandrogens such as flutamide, which inhibits androgen uptake, or estrogens are administered.
Despite antimetastatic benefits for patients, hormone therapy shows several adverse side effects, including osteoporosis [9].

Figure 2. Bone metastasis-targeting drug candidates. Several therapeutic approaches exist to target different steps of the metastatic cascade. For example, the EMT process represents a possible therapeutic intervention point, and inhibitors against TGFBR1 and EGFR1 are currently being tested in clinical trials. Homing and colonization of the metastatic niche by disseminating cancer cells can be targeted using CXCR4 or E-selectin antagonists. Drug candidates targeting dormant tumor cells include AXL and TGFBR2 inhibitors. Bisphosphonates and the anti-RANK-L antibody denosumab can be used to inhibit osteoclast-mediated bone remodeling. Finally, several immunotherapeutic approaches to fight bone metastasis have been explored, including PD-L1 or CTLA-4 checkpoint inhibitors, CAR-T cell therapy and depletion of Tregs with anti-CD25 antibodies. Besides T cells, other immune cell types represent promising candidates for therapeutic targeting, including neutrophils, tumor-associated macrophages (TAMs), lymphoid cells, myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs). Created with BioRender.com (accessed on 27 August 2021).

While the therein-mentioned treatment options aim to target established metastases, one way to block metastatic spread already at an early progression step could be to prevent EMT. Therefore, signaling pathways that trigger the EMT process may serve promising therapeutic targets. In part, EMT-associated processes are regulated by TGF-β, EGF and PDGF-β signaling, and inhibitors blocking TGF-β receptor type 1 (e.g., LY364947) [267–269] and EGFR type 1 (erlotinib and gefitinib) [270] are currently tested in clinical trials of bone-metastatic disease (Figure 2). Two studies recently described the mechanisms of early dissemination in breast cancer, demonstrating how switching off MAPK and turning on HER2 signaling pathways can activate the EMT process in this cancer [18,271]. Based on the MMTV-Her2 breast cancer mouse model, it was postulated that only a subpopulation of early breast cancer cells with either a Her2+/Skp2high+/Tpl2low+, phospho-MAPKlow+, CDH1low+, Twist1high+, CK8/18high+, Wnt-high, phospho-MAPKlow+, Twist1high+, CDH1low+ phenotype can disseminate and metastasize. Studies have also underlined a role for MAPKα/β kinases and activating transcription factor 2 (ATF2) in antagonizing Her2 signaling early in cancer progression, and a role of ATF2-mediated blockade of β-catenin activity. In addition, ZEB1, a key player in EMT and the formation
of metastatic precursor lesions, was demonstrated to be controlled by miR-1199-5p and miR-200 family members in a double-negative feedback loop [272,273]. Together, these mechanistic findings may open new avenues to target early tumor cell dissemination and prevent bone metastasis in the future.

The formation of the bone metastatic niche and the homing process, which supports the persistence of cancer cells in the new environment, may serve as an alternative therapeutic target. In the homing of breast cancer cells to the bone, E-selectin plays a critical role. By use of the small molecule E-selectin antagonist GMI-1271 (uproleselan) it was shown that inhibition of this molecule significantly prevented entry of breast cancer cells into the bone marrow in pre-clinical models. Therefore, this compound is currently being considered for clinical testing in solid tumors [274] (Figure 2). Integrins critically assist in the formation of the metastatic niche, and molecules such as α5β3 and α4β1 integrins promote the adhesion to ECM components [275]. In addition, ANXA2 and its receptor are critically involved in the adhesion and communication of cancer cells with osteoblasts [63]. Therefore, these factors may also serve as potential targets of therapeutic intervention in the bone metastatic process. Importantly, it has been suggested that homing of disseminated tumor cells to the bone marrow is reversible, thus offering an attractive therapeutic option to potentially kick out these cancer cells from niches where they have become domesticated. Experimentally, plerixafor (a CXCR4 antagonist) has been shown to mobilize disseminated cancer cells from their niches back to the bloodstream [276]. By preventing CXCL12/CXCR4 crosstalk, exposure to plerixafor resulted in reduced ERK1/2 signaling and consequently, decreased proliferation and invasion of disseminated tumor cells (Figure 2).

To target mechanisms responsible for formation of the metastatic niche and of factors activating the dormant state of cancer cells, inhibitors of AXL and TGF-β2 signaling pathways may offer therapeutic options. In cases involving prostate cancer cells, the ANXA2/ANXA2R axis and the GAS6-AXL interaction, which both induce dormancy of cancer cells in the bone microenvironment [277], may represent rational targets for the therapy of skeletal metastasis [278] (Figure 2).

As mentioned earlier, osteoblasts and osteoclasts play important roles in transitions between dormancy and reactivation of disseminated cancer cells. However, mechanisms regulating the timing of dormant tumor cell reactivation leading to metastasis remain an enigma, as do those keeping tumor cells dormant. It is largely unclear how osteoblasts switch from a “dormancy-promoting” to a “metastasis-promoting” state. Recent evidence suggests that bone metastatic breast cancer cells can reprogram osteoblasts in the bone marrow niche to produce altered amounts of decorin and CCN3, which leads to the inhibition of tumor cell proliferation via upregulation of p21 expression. This “tumor-educated” subpopulation of OPNhigh, smooth muscle actin (SMA)low, IL-6low osteoblasts may therefore play a critical role in engaging disseminated breast cancer cells into dormancy in early disease [279]. Osteoblasts certainly represent promising candidates for therapeutic targeting to aid in the restriction of metastatic outgrowth in the bone niche. The question remains how one may practically turn this transient dormancy phenotype into a state of permanent metastatic dormancy in a clinical setting.

3.2. Potentials for Immunotherapy

Bone marrow represents a unique immune microenvironment containing a complex composition of immune cells that may actually provide an immune-privileged niche for disseminated tumor cells [280]. The diverse interplay between immune cells and the skeletal system has been extensively reviewed elsewhere [281–283]. Importantly, tumor cells can create an immunosuppressive bone metastatic microenvironment, which leads to low response rates to different cancer therapies [84]. Briefly, the repertoire of immune cells in the bone marrow niche includes T cells [284], macrophages [285], dendritic cells (DCs) [286], natural killer (NK) cells and myeloid-derived suppressor cells [287]. For example, cytotoxic CD8+ T cells can release TNF-α and interferon (IFN)-γ to eliminate tumor cells. The presence of CD4+ CD25high regulatory T cells (Tregs) in the tumor and
blood of cancer patients predicts poor prognosis and Tregs are significantly increased in the bone marrow of patients with prostate cancer that has metastasized to the bone [288]. Therefore, depleting Tregs in the bone microenvironment may provide a means to prevent bone metastasis.

NK cells represent another important cell type in immune-mediated tumor killing through granzyme B- and perforin-mediated apoptosis or Fas–Fas ligand interactions. Depletion of NK cells causes uncontrolled tumor growth and metastasis. Thus, therapy with NK cells modified to recognize antigens specifically expressed on the surface of cancer cells and to produce cytokines such as IL-2 and IL-15, which increase their survival capacity and proliferation and promote antitumor activity in vivo, provides another treatment option for bone metastasis [289]. The combination of therapy with NK cell-stimulating cytokines (IL-2, IL-12, IL-15 and IL-21), reagents against activities limiting NK cell functionality (anti-KIR/anti-PD1 monoclonal antibodies, Treg depletion) and reagents enhancing tumor cell recognition (monoclonal antibodies, bi/trispecific targeting reagents, chimeric antigen receptors) may hold promise in future NK cell-mediated antitumor therapy [290] (Figure 2).

Tumor-associated M2 polarized macrophages (TAMs) promote tumor cell to bone metastasis through CCL2/CCR2 or colony-stimulating factor 1 (CSF1)/CSF1R signaling. Blocking the CCL2/CCLR2 axis can suppress the accumulation of TAMs in tumors as well as reducing metastasis in animal models [291]. Monoclonal antibodies (emactuzumab, cabiralizumab and PD-0360324) and the small molecule pexidartinib (PLX3397) targeting CSF1/CSF1R signaling were demonstrated to reduce the number of TAMs and prevent metastasis in several solid tumors [292,293] (Figure 2). In addition, several compounds including trabectedin, cladronate and zoledronic acid were reported to deplete macrophages by inducing apoptosis [294]. Macrophage polarization may be reprogrammed to tumor cell killing by treatment with tyrosine kinase inhibitors sunitinib and sorafenib, or fenretinide [4-hydroxy (phenyl) retinamide], which inhibit STAT3 or STAT6 in macrophages, thereby blocking IL-10 secretion [295,296].

Dendritic cells suppress the cytotoxic capacity of CD8+ T cells via production of various molecules, including arginase I, nitric oxide, TGF-β or IL-10. Dysfunctional DCs can be converted into functional DCs by microtubule destabilizing agents (dolastatin 10 and ansamitocin P3) switching DCs from immunosuppressive to immune-activating by provoking phenotypic and functional DC maturation [297] (Figure 2). Vaccination with tumor antigen-loaded DCs may also provide a means of activating an immune response against bone-metastatic disease [298].

Myeloid-derived suppressor cells (MDSCs) release chemokines including IL-6, VEGF, FGF-2 and MMP-9 to promote cancer progression and bone metastasis. MDSC-targeted therapeutic approaches comprise several modalities: anti-GR-1 antibodies; chemotherapeutic agents (5FU, paclitaxel, gemcitabine, cisplatin, docetaxel and lurbinecetin); phosphodiesterase 5 (PDE5) inhibitors (sildenafil, tadafafil and vardenafil); vemurafenib as well as zoledronic acid, which cause MDSC apoptosis; the mTOR inhibitor rapamycin; STAT3 inhibitors (AG490, CPA7, S3I-201 and statistic) deactivating MDSCs; all-trans-retinoic acid (ATRA) or vitamin D promoting MDSC differentiation into nonsuppressive macrophages and DCs; the COX2 inhibitor celecoxib and nonsteroidal anti-inflammatory drugs (e.g., aspirin); TLRs (sunitinib and sorafenib); antagonists for chemokine receptors (CCR2, CXC1R2 and CXCR4) or chemokines (CCL2, CXCL5 and CXCL12) preventing the recruitment of MDSCs from the bone marrow into the tumor microenvironment [280] (Figure 2).

Tumor-associated neutrophils are able to release CXCR4, VEGF and MMP-9 to promote tumor bone metastasis. Targeting any of these immune cells represents a promising avenue for cell-based cancer therapies. This may be achieved by inhibition of CXCR2 or IL-17 to reduce neutrophil migration into the tumor, or by anti-TGF-β that leads to a shift from N2 to the N1 phenotype of neutrophils with subsequent acquisition of antitumor activity [299–301] (Figure 2).
Recently, it was shown in mouse tumor models and patients with breast cancer that inhibition of RANK signaling induces an antitumor immune response orchestrated by CD8+ T cells. In addition, tumors appear to be more sensitive to anti-programmed death ligand 1 (PD-L1) and/or anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) after inhibiting the RANK signaling pathway in tumor cells. This study suggests the use of RANK pathway inhibitors to prime luminal breast cancer for immunotherapy [302]. The TGF-β molecule, which promotes bone metastasis and whose excessive amounts produced from osteoclast-activated tumors completely remodel the bone surface, represents another promising immunotherapy target. Anti-TGF-β treatment was shown to restore functions of Th1 cells, boost immunotherapy and inhibit tumor growth [303].

A number of other immunotherapeutic approaches to fight bone metastasis have been explored. These include chimeric antigen receptor (CAR)-T cell therapy, depletion of Tregs with anti-CD25 antibody (e.g., daclizumab and basiliximab) alone or in combination with cyclophosphamide, fludarabine and paclitaxel-based chemotherapy, or antibodies against immunosuppressive CTLA-4 such as ipilimumab and tremelimumab [280] (Figure 2). In fact, clear evidence that patients with bone metastases would benefit from immune cell-targeted therapies is still lacking. Furthermore, it is important to note that immunotherapies are associated with skeletal-related adverse effects such as compression of the spinal cord, or fractures and lesions caused by increased bone resorption [304,305]. Recently, the concept of osteoimmuno-oncology has been introduced, which takes into account the interactions between tumor, immune and bone cells in the bone microenvironment and may thus provide the basis for the development of more effective immunotherapies against bone metastasis in the future [281].

4. Conclusions

Bone metastases are a very common and fatal complication for cancer patients. They worsen the quality of life and are associated with an increase in morbidity and mortality. Established bone metastases are difficult to eradicate with current treatment modalities and increase the risk for further tumor dissemination and progression of treatment-resistant disease. This is due to a complex and reciprocal interplay between tumor cells and the microenvironment in the bone niche. Effective treatments of bone metastatic disease therefore need to block the communication between tumor cells and the various cellular and noncellular components of the host compartment at an early progression stage. To this end, a better understanding of the early steps of metastasis such as pre-metastatic niche formation, escape of tumor cells from the primary site and colonization of the bone is crucial. This may lead to the identification of reliable biomarkers for early diagnosis, which represents a key strategy for the disruption of these early events. In particular, finding ways to prolong or maintain tumor cell dormancy in order to prevent the emergence of overt metastases is an important area for further research. Despite these challenges, advances in our understanding of the bone metastatic process have resulted in the emergence of numerous promising therapies, which target bone cells and/or the bone microenvironment. A recent review provides a comprehensive list of these therapies in current clinical development for the therapy of bone metastases [10]. Furthermore, recent immunotherapeutic developments may hold promise, however, an in-depth knowledge of the immune escape mechanisms utilized by bone metastatic cancers, specifically sarcomas, is urgently warranted. Major attention should also be drawn on the role of the immune microenvironment in controlling disease progression and resistance to therapies. Finally, validation of novel therapeutic approaches requires testing in pre-clinical models of bone metastasis, which are not yet uniformly available for all bone metastatic cancer entities. While genetically engineered animal models for bone metastatic cancer are scarce, novel patient-derived xenograft models, as well as in vitro organoid and scaffold models recapitulating the bone niche, may be increasingly used to accelerate the development of bone metastasis-targeting compounds [259,306–311]. This most likely requires a joint and multidisciplinary effort between industry and academia to be eventually successful.
Author Contributions: J.B. and V.F. conceptualized and wrote the manuscript; D.N.T.A. and H.K. commented on and modified the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Austrian Science Fund (FWF), grant number P34341-B. Open Access Funding by the Austrian Science Fund (FWF).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

References
1. Dillekas, H.; Rogers, M.S.; Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019, 8, 5574–5576. [CrossRef]
2. Weilbaecher, K.N.; Guise, T.A.; McCauley, L.K. Cancer to bone: A fatal attraction. Nat. Rev. Cancer 2011, 11, 411–425. [CrossRef]
3. Stamatopoulos, A.; Stamatopoulos, T.; Gamie, Z.; Kenanidis, E.; Ribeiro, R.D.C.; Rankin, K.S.; Gerrand, C.; Dalgarno, K.; Tsiridis, E. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. J. Bone Oncol. 2019, 16, 100231. [CrossRef] [PubMed]
4. Huang, J.F.; Shen, J.; Li, X.; Rengan, R.; Silvestris, N.; Wang, M.; Derosa, L.; Zheng, X.; Belli, A.; Zhang, X.L.; et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: A large population-based study. Ann. Transl. Med. 2020, 8, 482. [CrossRef] [PubMed]
5. Morgan, T.M.; Lange, P.H.; Porter, M.P.; Lin, D.W.; Ellis, W.J.; Gallaher, I.S.; Vessella, R.L. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin. Cancer Res. 2009, 15, 677–683. [CrossRef]
6. Tjensvoll, K.; Oltedal, S.; Heikkilä, R.; Kvaløy, J.T.; Gilje, B.; Reuben, J.M.; Smaaland, R.; Nordgård, O. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer 2012, 12, 190. [CrossRef] [PubMed]
7. Hochheuser, C.; Windt, L.J.; Kunze, N.Y.; de Vos, D.L.; Tytgat, G.A.M.; Voermans, C.; Timerman, I. Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications. Stem Cells Dev. 2021, 30, 59–78. [CrossRef]
8. Zhang, Y.; Zhang, L.; Zhang, G.; Li, S.; Duan, J.; Cheng, J.; Ding, G.; Zhou, C.; Zhang, J.; Luo, P.; et al. Osteosarcoma metastasis: Prospective role of ezrin. Tumour Biol. 2014, 35, 5055–5059. [CrossRef]
9. Vogelzang, N.J.; Coleman, R.E.; Michalski, J.M.; Nilsson, S.; O’Sullivan, J.M.; Parker, C.; Widmark, A.; Thueson, M.; Xu, L.; Germino, J.; et al. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin. Genitourin Cancer 2017, 15, 42–52.e8. [CrossRef]
10. Coleman, R.E.; Croucher, P.L.; Padhani, A.R.; Clézardin, P.; Chow, E.; Fallon, M.; Guise, T.; Colangieli, S.; Capanna, R.; Costa, L. Bone metastases. Nat. Rev. Dis. Primers 2016, 6, 83. [CrossRef]
11. Obenauf, A.C.; Massagué, J. Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer 2015, 1, 76–91. [CrossRef] [PubMed]
12. Zhang, X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Cancer Commun. 2019, 39, 76. [CrossRef]
13. Croucher, P.L.; McDonald, M.M.; Martin, T.J. Bone metastasis: The importance of the neighbourhood. Nat. Rev. Cancer 2016, 16, 373–386. [CrossRef]
14. Macedo, F.; Ladeira, K.; Pinho, F.; Saraiva, N.; Bonito, N.; Pinto, L.; Goncalves, F. Bone Metastases: An Overview. Oncol. Rev. 2017, 11, 321. [CrossRef]
15. Clézardin, P.; Coleman, R.; Puppio, M.; Ottewell, P.; Bonnelly, E.; Paycha, F.; Confavreux, C.B.; Holen, I. Bone metastasis: Mechanisms, therapies, and biomarkers. Physiol. Rev. 2021, 101, 797–855. [CrossRef] [PubMed]
16. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339, 580–584. [CrossRef]
17. Fares, J.; Fares, M.Y.; Khachfe, H.H.; Salhab, H.A.; Fares, Y. Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct. Target. Ther. 2020, 5, 28. [CrossRef] [PubMed]
18. Harper, K.L.; Sosa, M.S.; Entenberg, D.; Hosseini, H.; Cheung, J.F.; Nobre, R.; Avivar-Valderas, A.; Nagi, C.; Girms, N.; Davis, R.J.; et al. Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature 2016, 540, 588–592. [CrossRef]
19. Klein, C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9, 302–312. [CrossRef]
20. Ottewell, P.D.; Wang, N.; Meek, J.; Fowles, C.A.; Croucher, P.L.; Eaton, C.L.; Holen, I. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr.-Relat. Cancer 2014, 21, 769–781. [CrossRef] [PubMed]
21. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275–292. [CrossRef]
22. Fidler, I.J. Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl. Cancer Inst. 1970, 45, 773–782. [PubMed]
23. Mehlen, P.; Puisieux, A. Metastasis: A question of life or death. Nat. Rev. Cancer 2006, 6, 449–458. [CrossRef]
24. Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, 12, 6243s–6249s. [CrossRef] [PubMed]

25. Guo, Z.; Zhang, C.; Guo, Q.; Xu, Y.; Feng, G.; Li, L.; Han, X.; Lu, F.; Ma, Y.; Wang, X.; et al. The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer. Cancer Manag. Res. 2018, 10, 1639–1646. [CrossRef]

26. Sathiakumar, N.; Delzell, E.; Morrisey, M.A.; Falkson, C.; Yong, M.; Chia, V.; Blackburn, J.; Arora, T.; Kilgore, M.L. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011, 14, 177–183. [CrossRef]

27. Zhang, W.; Bado, I.L.; Hu, J.; Wan, Y.W.; Wu, L.; Wang, H.; Gao, Y.; Jeong, H.H.; Xu, Z.; Hao, X.; et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell 2021, 184, 2471–2486.e20. [CrossRef]

28. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871–890. [CrossRef] [PubMed]

29. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [CrossRef] [PubMed]

30. Ottewell, P.D.; O’Donnell, L.; Holen, I. Molecular alterations that drive breast cancer metastasis to bone. Bonekey Rep. 2015, 4, 643. [PubMed]

31. Thiery, J.P.; Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2007, 8, 131–142. [CrossRef] [PubMed]

32. Thompson, E.W.; Paik, S.; Brünner, N.; Sommers, C.L.; Zugmaier, G.; Clarke, R.; Shima, T.B.; Torri, J.; Donahue, S.; Lippman, M.E.; et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol. 1992, 150, 534–544. [CrossRef] [PubMed]

33. Sommers, C.L.; Heckford, S.E.; Skerker, J.M.; Worland, P.; Torri, J.A.; Thompson, E.W.; Byers, S.W.; Gelmann, E.P. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastic-resistant human breast cancer cell lines. Cancer Res. 1992, 52, 5190–5197. [PubMed]

34. Gilles, C.; Polette, M.; Zahm, J.M.; Tournier, J.M.; Volders, L.; Foidart, J.M.; Birembaut, P. Vimentin contributes to human mammary epithelial cell migration. J. Cell Sci 1999, 112 Pt. 24, 4615–4625. [CrossRef]

35. Nieman, M.T.; Prudoff, R.S.; Johnson, K.R.; Wheelock, M.J. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J. Cell Biol. 1999, 147, 631–644. [CrossRef]

36. Hazan, R.B.; Phillips, G.R.; Qiao, Y.F.; Norton, L.; Aaronson, S.A. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 2000, 148, 779–790. [CrossRef] [PubMed]

37. Tomita, K.; van Bokhoven, A.; van Leenders, G.J.; Ruijter, E.T.; Jansen, C.F.; Bussemakers, M.J.; Schalken, J.A. Cadherin switching in human prostate cancer progression. Cancer Res. 2000, 60, 3650–3654.

38. Jaggi, M.; Nazemi, T.; Abrahams, N.A.; Baker, J.J.; Galich, A.; Smith, L.M.; Balaji, K.C. N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 2006, 66, 193–199. [CrossRef] [PubMed]

39. McAllhany, S.J.; Ayala, G.E.; Frolov, A.; Ressler, S.J.; Wheeler, T.M.; Watson, J.E.; Collins, C.; Rowley, D.R. Decreased stromal expression and increased epithelial expression of WDFC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate 2004, 61, 182–191. [CrossRef]

40. Derycke, L.; De Wever, O.; Stove, V.; Vanhoecke, B.; Delanghe, J.; Depypere, H.; Bracke, M. Soluble N-cadherin in human biological fluids. Int. J. Cancer. 2009, 115, 2899–2905. [CrossRef]

41. Chunthapong, J.; Seftor, E.A.; Khalkhali-Ellis, Z.; Seftor, R.E.; Amir, S.; Lubaroff, D.M.; Heidger, P.M., Jr.; Hendrix, M.J. Dual roles of E-cadherin in prostate cancer invasion. J. Cell. Biochem. 2004, 91, 649–661. [CrossRef]

42. Lu, Z.; Ghosh, S.; Wang, Z.; Hunter, T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4, 499–515. [CrossRef]

43. Wells, C.M.; Ahmed, T.; Masters, J.R.; Jones, G.E. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil. Cytoskeleton. 2005, 62, 180–194. [CrossRef] [PubMed]

44. Alexander, N.R.; Tran, N.L.; Rekapalli, H.; Summers, C.E.; Glackin, C.; Heimark, R.L. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res. 2006, 66, 3365–3369. [CrossRef] [PubMed]

45. Kwok, W.K.; Ling, M.T.; Lee, T.W.; Lau, T.C.; Zhou, C.; Zhang, X.; Chua, C.W.; Chan, K.W.; Chan, F.L.; Glackin, C.; et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005, 65, 5153–5162. [CrossRef]

46. Gu, X.; Zerbini, L.F.; Otu, H.H.; Bhasin, M.; Yang, Q.; Joseph, M.G.; Grall, F.; Onatunde, T.; Correa, R.G.; Libermann, T.A. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res. 2007, 67, 4219–4226. [CrossRef] [PubMed]

47. Veversis-Lowe, T.L.; Lawrence, M.G.; Collard, R.L.; Bui, L.; Herington, A.C.; Nicol, D.L.; Clements, J.A. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr.-Relat. Cancer 2005, 12, 631–643. [CrossRef] [PubMed]

48. Whitbread, A.K.; Veversis-Lowe, T.L.; Lawrence, M.G.; Nicol, D.L.; Clements, J.A. The role of kallikrein-related peptidases in prostate cancer: Potential involvement in an epithelial to mesenchymal transition. Biol. Chem. 2006, 378, 707–714. [CrossRef] [PubMed]
49. Yang, S.; Zhong, C.; Frenkel, B.; Reddi, A.H.; Roy-Burman, P. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. *Cancer Res.* 2005, 65, 5769–5777. [CrossRef]
50. Xu, J.; Wang, R.; Xie, Z.H.; Odeno-Marah, V.; Pathak, S.; Multani, A.; Chung, L.W.; Zhai, H.E. Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. *Prostate* 2006, 66, 1664–1673. [CrossRef]
51. Paget, S. The distribution of secondary growths in cancer of the breast. *Cancer Metastasis Rev.* 1989, 8, 98–101. [CrossRef]
52. Mazo, I.B.; von Andrian, U.H. Adhesion and homing of blood-borne cells in bone marrow microvessels. *J. Leukoc. Biol.* 1999, 66, 25–32. [CrossRef] [PubMed]
53. Bussard, K.M.; Gay, C.V.; Mastro, A.M. The bone microenvironment in metastasis; what is special about bone? *Cancer Metastasis Rev.* 2008, 27, 41–55. [CrossRef]
54. Ren, G.; Esposito, M.; Kang, Y. Bone metastasis and the metastatic niche. *J. Mol. Med.* 2015, 93, 1203–1212. [CrossRef]
55. Liu, Y.; Cao, X. Characteristics and Significance of the Pre-metastatic Niche. *Cancer Cell* 2016, 30, 668–681. [CrossRef]
56. Zhang, X.H.; Jin, X.; Malladi, S.; Zou, Y.; Wen, Y.H.; Brogi, E.; Smid, M.; Foeckens, J.A.; Massague, J. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. *Cell* 2013, 154, 1060–1073. [CrossRef]
57. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature 2001*, 410, 50–56. [CrossRef] [PubMed]
58. Teicher, B.A.; Fricker, S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. *Clin. Cancer Res.* 2010, 16, 2927–2931. [CrossRef] [PubMed]
59. Taichman, R.S.; Cooper, C.; Keller, E.T.; Pienta, K.J.; Taichman, N.S.; McCauley, L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. *Cancer Res.* 2002, 62, 1832–1837.
60. Wang, J.; Loberg, R.; Taichman, R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. *Cancer Metastasis Rev.* 2006, 25, 573–587. [CrossRef]
61. Hung, C.S.; Su, H.Y.; Liang, H.H.; Lai, C.W.; Chang, Y.C.; Ho, Y.S.; Wu, C.H.; Ho, J.D.; Wei, P.L.; Chang, Y.J. High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases. *Tumour Biol.* 2014, 35, 1581–1588. [CrossRef] [PubMed]
62. Shiozawa, Y.; Havens, A.M.; Jung, Y.; Ziegler, A.M.; Pedersen, E.A.; Wang, J.; Wang, J.; Lu, G.; Roodman, G.D.; Loberg, R.D.; et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. *J. Cell. Biochem.* 2008, 105, 370–380. [CrossRef] [PubMed]
63. Jung, Y.; Wang, J.; Lee, E.; McGee, S.; Berry, J.E.; Yumoto, K.; Dai, J.; Keller, E.T.; Shiozawa, Y.; Taichman, R.S. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. *Mol. Cancer Res.* 2015, 13, 197–207. [CrossRef] [PubMed]
64. Chu, G.C.; Zhau, H.E.; Wang, R.; Rogatko, A.; Feng, X.; Zayzafoon, M.; Liu, Y.; Farach-Carson, M.C.; You, S.; Kim, J.; et al. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. *Br. J. Cancer* 2006, 95, 5769–5777. [CrossRef] [PubMed]
65. Woodward, J.K.; Holen, I.; Coleman, R.E.; Buttle, D.J. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. *Bone* 2007, 41, 912–927. [CrossRef]
66. Winkler, J.; Abisoye-Ogunniyan, A.; Metcalf, K.J.; Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. *Nat. Review. 2020*, 21, 5120. [CrossRef]
67. Casimiro, S.; Mohammad, K.S.; Pires, R.; Tato-Costa, J.; Alho, I.; Teixeira, R.; Carvalho, A.; Ribeiro, S.; Lipton, A.; Guise, T.A.; et al. miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Metastasis Rev.* 2013, 32, 41–56. [CrossRef] [PubMed]
68. Cox, T.R.; Rumney, R.M.H.; Schoof, E.M.; Perryman, L.; Hoyle, A.M.; Agrawal, A.; Bird, D.; Latif, N.A.; Forrest, H.; Evans, H.R.; et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. *Nature* 2015, 522, 106–110. [CrossRef]
69. Zoni, E.; van der Pluijm, G. The role of microRNAs in bone metastasis. *J. Bone Oncol.* 2016, 5, 104–108. [CrossRef]
70. Ell, B.; Mercatali, L.; Ibrahim, T.; Campbell, N.; Schwarzenbach, H.; Pantel, K.; Amadori, D.; Kang, Y. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Cell* 2013, 24, 542–556. [CrossRef]
71. McCabe, N.P.; De, S.; Vasani, A.; Brainard, J.; Byzova, T.V. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. *Oncogene* 2007, 26, 6238–6243. [CrossRef] [PubMed]
72. Sloan, E.K.; Pouliot, N.; Stanley, K.L.; Chia, J.; Moseley, J.M.; Hards, D.K.; Anderson, R.L. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. *Breast Cancer Res.* 2006, 8, R20. [CrossRef] [PubMed]
73. Chang, A.C.; Chen, P.C.; Lin, Y.F.; Su, C.M.; Liu, J.F.; Lin, T.H.; Chuang, S.M.; Tang, C.H. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system. *Cancer Lett.* 2018, 426, 47–56. [CrossRef] [PubMed]
74. Eyre, R.; Alferaz, D.G.; Santiago-Gomez, A.; Spence, K.; McConnell, J.C.; Hart, C.; Simoes, B.M.; Lefley, D.; Tulotta, C.; Storer, J.; et al. Microenvironmental IL1beta promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. *Nat. Commun.* 2019, 10, 5016. [CrossRef] [PubMed]
75. Price, T.T.; Burness, M.L.; Sivan, A.; Warner, M.J.; Cheng, R.; Lee, C.H.; Olivere, L.; Comatas, K.; Magnani, J.; Kim Lyerly, H.; et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. *Sci. Transl. Med.* 2016, 8, 340ra373. [CrossRef]
76. Esposito, M.; Mondal, N.; Greco, T.M.; Wei, Y.; Spadazzi, C.; Lin, S.C.; Zheng, H.; Cheung, C.; Magnani, J.L.; Lin, S.H.; et al. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat. Cell Biol. 2019, 21, 627–639. [CrossRef] [PubMed]

77. Haider, M.T.; Smit, D.J.; Taipaleenmäki, H. The Endostele Niche in Breast Cancer Bone Metastasis. Front. Oncol. 2020, 10, 335. [CrossRef]

78. Mayhew, V.; Omokheinde, T.; Johnson, R.W. Tumor dormancy in bone. Cancer Rep. 2020, 3, e1156. [CrossRef]

79. Templeton, Z.S.; Lie, W.R.; Wang, W.; Rosenberg-Hasson, Y.; Alluri, R.V.; Tamaresis, J.S.; Bachmann, M.H.; Lee, K.; Maloney, W.J.; Contag, C.H.; et al. Breast Cancer Cell Colonization of the Human Bone Marrow Adipose Tissue Niche. Neoplasia 2015, 17, 849–861. [CrossRef]

80. Ghajer, C.M.; Peinado, H.; Mori, H.; Matei, I.R.; Evasion, K.J.; Brazier, H.; Almeida, D.; Koller, A.; Hajjar, K.A.; Stainier, D.Y.; et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15, 807–817. [CrossRef]

81. Shiroy, Y.; Pedersen, E.A.; Havens, A.M.; Jung, Y.; Mishra, A.; Joseph, J.; Kim, J.K.; Patel, L.R.; Ying, C.; Ziegler, A.M.; et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish foci in mouse bone marrow. J. Clin. Invest. 2011, 121, 1298–1312. [CrossRef] [PubMed]

82. Mohme, M.; Riethdorf, S.; Pantel, K. Circulating and disseminated tumour cells—Mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 2017, 14, 155–167. [CrossRef] [PubMed]

83. Rucci, N.; Teti, A. Osteomimicry: How the Seed Grows in the Soil. Calcif. Tissue Int. 2018, 102, 131–140. [CrossRef]

84. Steinzein, Z.Z.; Pamarthy, S.; Sagar, V.; Costa, R.; Abdulkadir, S.A.; Giles, F.J.; Carneiro, B.A. Overcoming immunosuppression in bone metastases. Crit. Rev. Oncol. Hematol. 2017, 114, 117–127. [CrossRef] [PubMed]

85. Yang, C.; Pan, H.; Shen, L. Pan-Cancer Analyses Reveal Prognostic Value of Osteomimicry Across 20 Solid Cancer Types. Front. Mol. Biosci. 2020, 7, 576269. [CrossRef]

86. Byrne, N.M.; Summers, M.A.; McDonald, M.M. Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities. JBMR Plus 2019, 3, e10125. [CrossRef]

87. Phan, T.G.; Croucher, P.I. The dormant cancer cell life cycle. Nat. Rev. Cancer 2020, 20, 398–411. [CrossRef] [PubMed]

88. Gomatou, G.; Syrigos, N.; Vathiotis, I.A.; Kotteas, E.A. Tumor Dormancy: Implications for Invasion and Metastasis. Int. J. Mol. Sci. 2021, 22, 4862. [CrossRef]

89. Kobayashi, A.; Okuda, H.; Xing, F.; Pandey, P.R.; Watabe, M.; Hirota, S.; Pai, S.K.; Liu, W.; Fukuda, K.; Chambers, C.; et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 2011, 208, 2641–2655. [CrossRef]

90. Bragado, P.; Estrada, Y.; Parikh, F.; Krause, S.; Capobianco, C.; Farina, H.G.; Schewe, D.M.; Aguirre-Ghiso, J.A. TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. [CrossRef]

91. Kan, C.; Vargas, G.; Pape, F.L.; Clezardin, P. Cancer Cell Colonisation in the Bone Microenvironment. Int. J. Mol. Sci. 2016, 17, 1674. [CrossRef] [PubMed]

92. Umoto, K.; Eber, M.R.; Wang, J.; Cackowski, F.C.; Decker, A.M.; Lee, E.; Nobre, A.R.; Aguirre-Ghiso, J.A.; Jung, Y.; Taichman, R.S. Axl is required for TGF-beta-induced dormancy of prostate cancer cells in the bone marrow. Sci. Rep. 2016, 6, 36520. [CrossRef] [PubMed]

93. Prunier, C.; Baker, D.; Ten Dijke, P.; Ritsma, L. TGF-β Family Signaling Pathways in Cellular Dormancy. Trends Cancer 2019, 5, 66–78. [CrossRef]

94. Chen, G.; Deng, C.; Li, Y.P. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 2012, 8, 272–288. [CrossRef]

95. Taichman, R.S.; Patel, L.R.; Bedenis, R.; Wang, J.; Weidner, S.; Schumann, T.; Umoto, K.; Berry, J.E.; Shiroy, Y.; Pienta, K.J. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE 2013, 8, e61873. [CrossRef]

96. Mishra, A.; Wang, J.; Shiroy, Y.; McGee, S.; Kim, J.; Jung, Y.; Joseph, J.; Berry, J.E.; Havens, A.; Pienta, K.J.; et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol. Cancer Res. 2012, 10, 703–712. [CrossRef]

97. Kusumbe, A.P.; Ramasamy, S.K.; Adams, R.H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 2014, 507, 323–328. [CrossRef] [PubMed]

98. Yu-Lee, L.Y.; Yu, G.; Lee, Y.C.; Lin, S.C.; Pan, J.; Pan, T.; Yu, K.J.; Liu, B.; Creighton, C.J.; Rodriguez-Canales, J.; et al. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone Via Activation of the TGFbetaRIII-p38MAPK-pS249/T252RB Pathway. Cancer Res. 2018, 78, 2911–2924. [CrossRef]

99. Ren, D.; Dai, Y.; Yang, Q.; Zhang, X.; Guo, W.; Ye, L.; Huang, S.; Chen, X.; Lai, Y.; Du, H.; et al. Wnt5a induces and maintains prostate cancer cells dormancy in bone. J. Exp. Med. 2019, 216, 428–449. [CrossRef]

100. Ono, M.; Kosaka, N.; Tominaga, N.; Yoshioka, Y.; Takeda, H.; Takahashi, R.U.; Yoshida, M.; Tsuda, H.; Tamura, K.; Ohchiya, T. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014, 7, ra63. [CrossRef]

101. Bliss, S.A.; Sinha, G.; Sandiford, O.A.; Williams, L.M.; Engelberth, D.J.; Guiro, K.; Idenalmhe, L.L.; Greco, S.J.; Ayer, S.; Bryan, M.; et al. Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. Cancer Res. 2016, 76, 5832–5844. [CrossRef]
102. Nobre, A.R.; Risson, E.; Singh, D.K.; Di Martino, J.S.; Cheung, J.F.; Wang, J.; Johnson, J.; Russnes, H.G.; Bravo-Cordero, J.J.; Birbrair, A.; et al. Bone marrow NG2+\textit{Nestin}+ mesenchymal stem cells drive DTC dormancy via TGF-β2. *Nat. Cancer 2021*, 2, 327–339. [CrossRef]

103. Vinay, D.S.; Ryan, E.P.; Pawelec, G.; Talib, W.H.; Stagg, J.; Elkord, E.; Lichtor, T.; Decker, W.K.; Whelan, R.L.; Kumara, H.; et al. Immune evasion in cancer. Mechanistic basis and therapeutic strategies. *Semin. Cancer Biol. 2015*, 35, S185–S198. [CrossRef]

104. Shupp, A.B.; Kolb, A.D.; Mukhopadhyay, D.; Bussard, K.M. Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoclasts. *Cancers 2018*, 10, 182. [CrossRef]

105. Lawson, M.A.; McDonald, M.M.; Kovacic, N.; Hua Khoo, W.; Terry, R.L.; Down, J.; Kaplan, W.; Paton-Hough, J.; Fellows, C.; Pettitt, J.A.; et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. *Nat. Commun. 2015*, 6, 6983. [CrossRef] [PubMed]

106. Ottewell, P.D.; Wang, N.; Brown, H.K.; Reeves, K.J.; Fowles, C.A.; Croucher, P.I.; Eaton, C.L.; Holen, I. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. *Clin. Cancer Res. 2014*, 20, 2922–2932. [CrossRef]

107. Ottewell, P.D.; Wang, N.; Brown, H.K., Fowles, C.A.; Croucher, P.I.; Eaton, C.L.; Holen, I. OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. *Int. J. Cancer 2015*, 137, 968–977. [CrossRef] [PubMed]

108. Lu, X.; Mu, E.; Wei, Y.; Riethdorf, S.; Yang, Q.; Yuan, M.; Yan, J.; Hua, Y.; Tiede, B.J.; Lu, X.; et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alphabeta1-positive osteoclast progenitors. *Cancer Cell 2011*, 20, 701–714. [CrossRef] [PubMed]

109. Wang, H.; Yu, C.; Gao, X.; Welte, T.; Muscarella, A.M.; Tian, L.; Zhao, H.; Zhao, Z.; Du, S.; Tao, J.; et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. *Cancer Cell 2015*, 27, 193–210. [CrossRef] [PubMed]

110. Luo, G.; He, Y.; Yu, X. Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis. *Front. Endocrinol. 2018*, 9, 339. [CrossRef]

111. Phadke, P.A.; Mercer, R.R.; Harms, J.F.; Jia, Y.; Frost, A.R.; Jewell, J.L.; Bussard, K.M.; Nelson, S.; Moore, C.; Kappes, J.C.; et al. Kinetics of metastatic breast cancer cell trafficking in bone. *Clin. Cancer Res. 2006*, 12, 1431–1440. [CrossRef] [PubMed]

112. Harvey, H.A.; Cream, L. Biology of bone metastases: Causes and consequences. *Clin. Breast Cancer 2007*, 7 (Suppl. 1), S7–S13. [CrossRef] [PubMed]

113. Liang, Y.; Zhang, H.; Song, X.; Yang, Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. *Semin. Cancer Biol. 2020*, 60, 14–27. [CrossRef]

114. Guise, T.A.; Yin, J.J.; Taylor, S.D.; Kumagai, Y.; Dallas, M.; Boyce, B.F.; Yoneda, T.; Mundy, G.R. Evidence for a causal role of calcium-sensing receptor signaling in bone promotes breast cancer growth in the bone of nude mice. *Cancer Cell 2010*, 16, 6–17. [CrossRef] [PubMed]

115. Coenegrachts, L.; Maes, C.; Torrekens, S.; Van Looveren, R.; Mazzone, M.; Guise, T.A.; Bouillon, R.; Stassen, J.M.; Carmeliet, P.; Carmeliet, G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. *Cancer Res. 2010*, 70, 6537–6547. [CrossRef]

116. Zhang, Y.; Zhou, H.; Song, X.; Yang, Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. *Semin. Cancer Biol. 2020*, 60, 14–27. [CrossRef]

117. Yamashita, J.; Inada, K.; Yamashita, S.; Nakashima, Y.; Matsuo, S.; Ogawa, M. Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer. *Int. J. Clin. Lab. Res. 1992*, 22, 227–230. [CrossRef] [PubMed]

118. Lev, D.C.; Kim, S.J.; Onn, A.; Stone, V.; Nam, D.H.; Yazici, S.; Fidler, I.J.; Price, J.E. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. *Clin. Cancer Res. 2005*, 11, 306–314. [CrossRef] [PubMed]

119. Zhang, X.H.; Wang, Q.; Gerald, W.; Huds, C.A.; Norton, L.; Smid, M.; Foekens, J.A.; Massagué, J. Latent bone metastasis in breast cancer tied to Srdc-dependent survival signals. *Cancer Cell 2009*, 16, 67–78. [CrossRef]

120. Meng, X.; Vander Ark, A.; Lee, P.; Hostetter, G.; Bhownick, N.A.; Matrisian, L.M.; Williams, B.O.; Miranti, C.K.; Li, X. Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis. *Oncogene 2016*, 35, 2370–2378. [CrossRef]

121. Kang, Y.; Siegel, P.M.; Shu, W.; Drobnjak, M.; Kakonen, S.M.; Cordon-Cardo, C.; Guise, T.A.; Massague, J. A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell 2003*, 3, 537–549. [CrossRef]

122. Coenegrachts, L.; Maes, C.; Torrekens, S.; Van Looveren, R.; Mazzone, M.; Guise, T.A.; Bouillon, R.; Stassen, J.M.; Carmeliet, P.; Carmeliet, G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. *Cancer Res. 2010*, 70, 6537–6547. [CrossRef]

123. Zheng, Y.; Zhou, H.; Fong-Yee, C.; Modzelewski, J.R.; Seibl, M.J.; Dunstan, C.R. Bone resorption increases tumour growth in a mouse model of osteoclastic breast cancer metastasis. *Clin. Exp. Metastasis 2008*, 25, 559–567. [CrossRef] [PubMed]

124. Zheng, Y.; Zhou, H.; Ooi, L.L.; Snir, A.D.; Dunstan, C.R.; Seibl, M.J. Vitamin D deficiency promotes prostate cancer growth in bone. *Prostate 2011*, 71, 1012–1021. [CrossRef] [PubMed]

125. Ooi, L.L.; Zhou, H.; Kalak, R.; Zheng, Y.; Conigrave, A.D.; Seibl, M.J.; Dunstan, C.R. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. *Cancer Res. 2010*, 70, 1835–1844. [CrossRef]

126. Kiefer, J.A.; Vessella, R.L.; Quinn, J.E.; Odman, A.M.; Zhang, J.; Keller, E.T.; Kestenuik, P.J.; Dunstan, C.R.; Corey, E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. *Clin. Exp. Metastasis 2004*, 21, 381–387. [CrossRef]
127. Corey, E.; Brown, L.G.; Quinn, J.E.; Poot, M.; Roudier, M.P.; Higano, C.S.; Vessella, R.L. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. *Clin. Cancer Res.* 2003, 9, 293–306.

128. Corey, E.; Brown, L.G.; Kiefer, J.A.; Quinn, J.E.; Pitts, T.E.; Blair, J.M.; Vessella, R.L. Osteoprotergerin in prostate cancer bone metastasis. *Cancer Res.* 2005, 65, 1710–1718. [CrossRef]

129. Karlsson, T.; Lundholm, M.; Widmark, A.; Persson, E. Tumor Cell-Derived Esosomes from the Prostate Cancer Cell Line TRAMP-C1 Impair Osteoclast Formation and Differentiation. *PLoS ONE* 2016, 11, e0166284. [CrossRef]

130. Nierste, B.A.; Glackin, C.A.; Kirshner, J. Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts. *Am. J. Blood Res.* 2014, 4, 73–85. [PubMed]

131. Abe, M.; Hiura, K.; Ozaki, S.; Kido, S.; Matsumoto, T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. *J. Bone Miner. Metab.* 2009, 27, 16–23. [CrossRef] [PubMed]

132. Body, J.J.; Casimiro, S.; Costa, L. Targeting bone metastases in prostate cancer: Improving clinical outcome. *Nat. Rev. Urol.* 2015, 12, 340–356. [CrossRef]

133. Wang, N.; Docherty, F.E.; Brown, H.K.; Reeves, K.J.; Fowles, A.C.; Ottewell, P.D.; Dear, T.N.; Holen, I.; Croucher, P.I.; Eaton, C.L. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: Evidence from in vivo models. *J. Bone Miner. Res.* 2014, 29, 2688–2696. [CrossRef] [PubMed]

134. Logothetis, C.J.; Lin, S.H. Osteoblasts in prostate cancer metastasis to bone. *Nat. Rev. Cancer* 2005, 5, 21–28. [CrossRef]

135. Yang, J.; Fizazi, K.; Peleg, S.; Sikes, C.R.; Raymond, A.K.; Jamal, N.; Hu, M.; Olive, M.; Martinez, L.A.; Wood, C.G.; et al. Prostate cancer cells induce osteoblast differentiation through a Cbfal-dependent pathway. *Cancer Res.* 2003, 61, 5652–5659. [PubMed]

136. Fizazi, K.; Yang, J.; Peleg, S.; Sikes, C.R.; Kreimann, E.L.; Daliani, D.; Olive, M.; Raymond, K.A.; Janus, T.J.; Logothetis, C.J.; et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotergerin in osteoblasts. *Clin. Cancer Res.* 2003, 9, 2587–2597.

137. Guise, T.A.; Mohammad, K.S.; Clines, G.; Stebbings, E.B.; Wong, D.H.; Higgins, L.S.; Vessella, R.; Corey, E.; Padalecki, S.; Suva, L.; et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. *Clin. Cancer Res.* 2006, 12, 6213s–6216s. [CrossRef]

138. Ottewell, P.D. The role of osteoblasts in bone metastasis. *J. Bone Oncol.* 2016, 5, 124–127. [CrossRef]

139. Clines, G.A.; Mohammad, K.S.; Bao, Y.; Stephens, O.W.; Suva, L.J.; Shaughnessy, J.D., Jr.; Fox, J.W.; Chirgwin, J.M.; Guise, T.A. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. *Mol. Endocrinol.* 2007, 21, 486–498. [CrossRef]

140. Roodman, G.D. Mechanisms of bone metastasis. *N. Engl. J. Med.* 2004, 350, 1655–1664. [CrossRef]

141. Itoh, T.; Ito, Y.; Ohtsuki, Y.; Ando, M.; Tsukamasa, Y.; Yamada, N.; Naoe, T.; Akao, Y. Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. *J. Mol. Histol.* 2012, 43, 509–515. [CrossRef] [PubMed]

142. Hashimoto, K.; Ochi, H.; Sumamura, S.; Kosaka, N.; Mabuchi, Y.; Fukuda, T.; Yao, K.; Kanda, H.; Ae, K.; Okawa, A.; et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. *Proc. Natl. Acad. Sci. USA* 2018, 115, 2204–2209. [CrossRef]

143. Ye, Y.; Li, S.L.; Ma, Y.Y.; Xiao, Y.J.; Yang, L.; Su, M.Q.; Li, Z.; Ji, Y.; Wang, J.; Lei, L.; et al. Exosomal mir-141-3p regulates osteoblast activity to promote the metastasis of prostate cancer cell. *Oncotarget* 2017, 8, 94834–94849. [CrossRef] [PubMed]

144. Tenta, R.; Sotirotou, E.; Pitsilis, T.; Thymoportunis, G.; Koutsilieris, M. Prostate cancer cell survival pathways activated by bone metastasis microenvironment. *J. Musculoskelet. Neuronal Interact.* 2005, 5, 135–144.

145. Yi, B.; Williams, P.J.; Niewolna, M.; Wang, Y.; Yoneda, T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. *Cancer Res.* 2002, 62, 917–923. [PubMed]

146. Stern, P.H.; Tattai, A.; Semler, D.E.; Lee, S.K.; Lakatos, P.; Strielean, P.J.; Tarjan, G.; Sanders, J.L. Endothelin receptors, second messengers, and actions in bone. *J. Nutr.* 1995, 125, 2028s–2032s. [CrossRef]

147. Saidak, Z.; Le Henaff, C.; Azzi, S.; Marty, C.; Da Nascimento, S.; Sonnet, P.; Marie, P.J. Wnt/β-catenin signaling mediates osteoblast differentiation triggered by peptide-induced α5β1 integrin priming in mesenchymal skeletal cells. *J. Biol. Chem.* 2015, 290, 6903–6912. [CrossRef]

148. Chen, Y.; Shi, H.Y.; Stock, S.R.; Stern, P.H.; Zhang, M. Regulation of breast cancer-induced bone lesions by β-catenin protein signaling. *J. Biol. Chem.* 2011, 286, 42575–42584. [CrossRef]

149. Bu, G.; Lu, W.; Liu, C.C.; Selander, K.; Yoneda, T.; Hall, C.; Keller, E.T.; Li, Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotergerin expression: Implication for breast cancer osteolytic bone metastases. *Int. J. Cancer* 2008, 123, 1034–1042. [CrossRef]

150. Velletri, T.; Xie, N.; Wang, Y.; Huang, Y.; Yang, Q.; Chen, X.; Chen, Q.; Shou, P.; Gan, Y.; Cao, G.; et al. P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development. *Cell Death Dis.* 2016, 7, e2015. [CrossRef] [PubMed]

151. Tian, W.; Li, Y.; Zhang, J.; Li, J.; Gao, J. Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures. *Gene* 2018, 650, 7–14. [CrossRef] [PubMed]

152. Mohseny, A.B.; Szuhai, K.; Romeo, S.; Buddingh, E.P.; Braire-de Bruijn, I.; de Jong, D.; van Pel, M.; Clayton-Jansen, A.M.; Hogendoorn, P.C. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. *J. Pathol.* 2009, 219, 294–305. [CrossRef] [PubMed]
153. Pietrovito, L.; Leo, A.; Gori, V.; Lulli, M.; Parri, M.; Becherucci, V.; Piccin, L.; Bambi, F.; Taddei, M.L.; Chiarugi, P. Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition. *Mol. Oncol.* 2018, 12, 659–676. [CrossRef]

154. Sun, T.; Zhong, X.; Song, H.; Liu, J.; Li, J.; Leung, F.; Lu, W.W.; Liu, Z.L. Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma. *Cell Death Dis.* 2019, 10, 298. [CrossRef] [PubMed]

155. Vallabhaneni, K.C.; Penfornis, P.; Dhule, S.; Guillonneau, F.; Adams, K.V.; Mo, Y.Y.; Xu, R.; Liu, Y.; Watabe, K.; Vemuri, M.C.; et al. Extracellular vesicles from bone marrow mesenchymal stem cells transport tumor regulatory microRNA, proteins, and metabolites. *Oncotarget* 2015, 6, 4953–4967. [CrossRef]

156. Avnet, S.; Di Pompo, G.; Chano, T.; Errani, C.; Ibrahim-Hashim, A.; Gillies, R.J.; Donati, D.M.; Baldini, N. Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation. *Int. J. Cancer* 2017, 140, 1331–1345. [CrossRef]

157. Zhang, H.; Wu, H.; Zheng, J.; Yu, P.; Xu, L.; Jiang, P.; Gao, J.; Wang, H.; Zhang, Y. Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. *Stem Cells* 2013, 31, 433–446. [CrossRef]

158. McMahon, S.; Charbonneau, M.; Grandmont, S.; Richard, D.E.; Dubois, C.M. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. *J. Biol. Chem.* 2006, 281, 24171–24181. [CrossRef]

159. Liu, M.; Wang, D.; Li, N. MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells. *Oncol. Res.* 2016, 23, 257–266. [CrossRef]

160. Zhou, Y.; Yang, C.; Wang, K.; Liu, X.; Liu, Q. MicroRNA-33b Inhibits the Proliferation and Migration of Osteosarcoma Cells via Targeting Hypoxia-Inducible Factor-1α. *Oncol. Res.* 2017, 25, 397–405. [CrossRef] [PubMed]

161. Zhang, Y.; Sun, S.; Chen, J.; Ren, P.; Hu, Y.; Cao, Z.; Sun, H.; Ding, Y. Oxytetracycline induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway. *Tumour Biol.* 2014, 35, 1619–1625. [CrossRef] [PubMed]

162. Huang, S.; Jin, A. ZIC2 promotes viability and invasion of human osteosarcoma cells using suppression HIPK2 expression and activating PI3K/AKT pathways. *J. Cell. Biochem.* 2018, 119, 2248–2257. [CrossRef] [PubMed]

163. Miao, J.H.; Wang, S.Q.; Zhang, M.H.; Yu, F.B.; Zhang, L.; Yu, Z.X.; Kuang, Y. Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway. *Oncol. Rep.* 2014, 32, 1497–1504. [CrossRef]

164. Kang, H.M.; Park, B.S.; Kang, H.K.; Park, H.R.; Yu, S.B.; Kim, I.R. Delphinidin induces apoptosis and inhibits epithelial-to-mesenchymal transition via the ERK/p38 MAPK-signaling pathway in human osteosarcoma cell lines. *Environ. Toxicol.* 2018, 33, 640–649. [CrossRef] [PubMed]

165. Kumar, R.M.; Fuchs, B. Hedgehog signaling inhibitors as anti-cancer agents in osteosarcoma. *Cancers* 2015, 7, 784–794. [CrossRef]

166. Chen, L.H.; Wang, W.; Yeung, W.; Deng, Y.; Yuan, P.; Mak, K.K. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. *Oncogene* 2014, 33, 4857–4866. [CrossRef]

167. Zhao, Z.; Jia, Q.; Wu, M.S.; Xie, X.; Wang, Y.; Song, G.; Zou, C.Y.; Tang, Q.; Lu, J.; Huang, G.; et al. Degalactotigonin, a Natural Compound from Solanum nigrum L., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation-Mediated Repression of the Hedgehog/Gli1 Pathway. *Clin. Cancer Res.* 2018, 24, 130–144. [CrossRef]

168. Matsuoka, K.; Bakiri, L.; Wolff, L.I.; Linder, M.; Mikels-Vigdal, A.; Patiño-García, A.; Schüller, F.; Hartmann, C.; Sibilia, M.; Wagner, E.F. Wnt signaling and Lox2promote aggressive osteosarcoma. *Cell Res.* 2020, 30, 885–901. [CrossRef]

169. Gustafson, C.T.; Mamo, T.; Shogren, K.L.; Maran, A.; Yaszemski, M.J. FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling. *Front. Pharmacol.* 2017, 8, 285. [CrossRef]

170. Vega, O.A.; Lucero, C.M.J.; Araya, H.F.; Jerez, S.; Tapia, J.C.; Antonelli, M.; Salazar-Onfray, F.; Las Heras, F.; Thaler, R.; Riester, S.M.; et al. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types. *J. Cell. Biochem.* 2017, 118, 3662–3674. [CrossRef]

171. Tian, H.; Zhou, T.; Chen, H.; Li, C.; Jiang, Z.; Lao, L.; Kahn, S.A.; Duarte, M.E.L.; Zhao, J.; Daubs, M.D.; et al. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway. *J. Orthop. Res.* 2019, 37, 1638–1648. [CrossRef] [PubMed]

172. Erkizan, H.V.; Uversky, V.N.; Toretsky, J.A. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing’s sarcoma. *Clin. Cancer Res.* 2010, 16, 4077–4083. [CrossRef]

173. Katschnig, A.M.; Kauer, M.O.; Schwentner, R.; Tomazou, E.M.; Mutz, C.N.; Linder, M.; Sibilia, M.; Alonso, J.; Aryee, D.N.T.; Kovar, H. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing’s sarcoma. *Oncogene* 2017, 36, 5995–6005. [CrossRef]

174. Chansky, H.A.; Barahmand-Pour, F.; Mei, Q.; Kahn-Farooqi, W.; Zielinska-Kwiatkowska, A.; Blackburn, M.; Chansky, E.U., 3rd; Bruckner, J.D.; Greenlee, T.K.; et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing sarcoma. *Oncogene* 2004, 23, 3505–3514. [CrossRef]

175. Francozetti, G.A.; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Irendelle, M.; Aubert, S.; Dirksen, U.; Bouvier, C.; de Pinieux, G.; Snaar-Jagalska, E.; et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. *Oncogene* 2017, 36, 3505–3514. [CrossRef]

176. Adane, B.; Alexe, G.; Seong, B.K.A.; Lu, D.; Hwang, E.E.; Hnisz, D.; Lareau, C.A.; Ross, L.; Lin, S.; Dela Cruz, F.S.; et al. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. *Cancer Cell* 2021, 39, 827–844.e10. [CrossRef]
177. Surdez, D.; Zaidi, S.; Grosssetete, S.; Laud-Duval, K.; Ferre, A.S.; Mous, L.; Vourch, T.; Tirole, E.; Pierron, G.; Raynal, V.; et al. STAG2 mutations alter CTGF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma. *Cancer Cell* **2021**, *39*, 810–826.e9. [CrossRef] [PubMed]

178. Bierbaum, L.; Katschnig, A.M.; Radic-Sarikas, B.; Kauer, M.O.; Petro, J.A.; Höglér, S.; Gürrhofer, E.; Pedot, G.; Schäfer, B.W.; Schwentner, R.; et al. YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. *Oncogenesis* **2021**, *10*, 2. [CrossRef] [PubMed]

179. Ban, J.; Bennani-Baiti, I.M.; Kauer, M.; Schaefer, K.L.; Poremba, C.; Jug, G.; Schwentner, R.; Smrzkova, O.; Muehlbacher, K.; Aryee, D.N.; et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing’s sarcoma. *Cancer Res.* **2008**, *68*, 7100–7109. [CrossRef]

180. Ting, S.C.; Kiefer, T.; Ehlert, K.; Goericke, S.L.; Hinze, R.; Ketteler, P.; Bechrakis, N.E.; Schildhaus, H.U. Bone metastasis of neuroblastoma invasiveness. *Carcinogenesis* **2015**, *36*, 4086–4097. [CrossRef] [PubMed]

181. Lissat, A.; Joerschke, M.; Shinde, D.A.; Braunschweig, T.; Meier, A.; Makowska, A.; Bortnick, R.; Henneke, P.; Herget, G.; Gorr, T.A.; et al. IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells. *BMC Cancer* **2015**, *15*, 552. [CrossRef] [PubMed]

182. Rübe, C.E.; van Valen, F.; Willert, F.; Palm, J.; Schuck, A.; Willich, N.; Winkelmann, W.; Jürgens, H.; Rübe, C. Ewing’s sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure. *Int. J. Radiat. Oncol. Biol. Phys.* **2003**, *56*, 1414–1425. [CrossRef]

183. Miller, I.V.; Raposo, G.; Welsch, U.; Fuzeres da Costa, O.; Thiel, U.; Lebar, M.; Maurer, M.; Bender, H.U.; von Luettichau, I.; Richter, G.H.; et al. First identification of Ewing’s sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. *Biol. Cell* **2013**, *105*, 289–303. [CrossRef]

184. Villasante, A.; Marturano-Kruik, A.; Ambati, S.R.; Liu, Z.; Godier-Furnemont, A.; Parsa, H.; Lee, B.W.; Moore, M.A.; Vunjak-Novakovic, G. Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. *Theranostics* **2016**, *6*, 1119–1130. [CrossRef]

185. Li, X.; Mc Gee-Lawrence, M.E.; Decker, M.; Westendorf, J.J. The Ewing’s sarcoma fusion protein, EWS-FLI1, binds Runx2 and blocks osteoblast differentiation. *J. Cell Biochem.* **2010**, *111*, 933–943. [CrossRef] [PubMed]

186. Redini, F.; Heymann, D. Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma. *Front. Oncol.* **2015**, *5*, 279. [CrossRef] [PubMed]

187. Lee, D.H.; Park, C.J.; Jang, S.; Cho, Y.U.; Seo, J.J.; Im, H.J.; Koh, K.N.; Cho, K.J.; Song, J.S.; Seo, E.J. Clinical and Cytogenetic Profiles of Rhabdomyosarcoma with Bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience. *Ann. Lab. Med.* **2018**, *38*, 132–138. [CrossRef]

188. Ting, S.C.; Kiefer, T.; Ehliert, K.; Goerlinck, S.L.; Hinze, R.; Ketteler, P.; Bechrakis, N.E.; Schildhaus, H.U. Bone metastasis of retinoblastoma five years after primary treatment. *Am. J. Ophthalmol. Case Rep.* **2020**, *19*, 100834. [CrossRef]

189. Bernard, R. N-myc disrupts protein kinase C-mediated signal transduction in neuroblastoma. *EMBO J.* **1991**, *10*, 1119–1125. [CrossRef]

190. Akeson, R.; Bernards, R. N-myc down regulates neural cell adhesion molecule expression in rat neuroblastoma. *Mol. Cell. Biol.* **1990**, *10*, 2012–2016. [CrossRef]

191. Teitz, T.; Inoue, M.; Valentine, M.B.; Zhu, K.; Rehg, J.E.; Zhao, W.; Finkelstein, D.; Wang, Y.D.; Johnson, M.D.; Calabrese, C.; et al. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. *PLoS ONE* **2015**, *10*, e0125616. [CrossRef]

192. Ulrich, H.; Ratajczak, M.Z.; Schneider, G.; Adinolfi, E.; Orioli, E.; Ferrazoli, E.G.; Glaser, T.; Correa-Velloso, J.; Martins, P.C.M.; Coutinho, F.; et al. Kinin and Purine Signaling Contributes to Neuroblastoma Metastasis. *Front. Pharmacol.* **2018**, *9*, 500. [CrossRef]

193. Airoldi, I.; Cocco, C.; Morandi, F.; Prigione, I.; Pistola, V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. *Cancer Immunol. Immunother.* **2008**, *57*, 541–548. [CrossRef] [PubMed]

194. Novakovic, G. Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. *Theranostics* **2015**, *6*, 289–303. [CrossRef] [PubMed]

195. Shankar, V.; Hori, H.; Kihira, K.; Lei, Q.; Toyoda, H.; Iwamoto, S.; Komada, Y. Mesenchymal stromal cell secretome up-regulates 47 kDa CXCR4 expression, and induce invasiveness in neuroblastoma cell lines. *PLoS ONE* **2015**, *10*, e0120069. [CrossRef] [PubMed]

196. Airoldi, I.; Cocco, C.; Morandi, F.; Prigione, I.; Pistoia, V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. *Cancer Immunol. Immunother.* **2008**, *57*, 541–548. [CrossRef] [PubMed]

197. Silverman, A.M.; Nakata, R.; Shimada, H.; Spoto, R.; DeClerck, Y.A. A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. *Cancer Res.* **2012**, *72*, 2228–2238. [CrossRef]

198. Shankar, V.; Hori, H.; Kihira, K.; Lei, Q.; Toyoda, H.; Iwamoto, S.; Komada, Y. Mesenchymal stromal cell secretome up-regulates 47 kDa CXCR4 expression, and induce invasiveness in neuroblastoma cell lines. *PLoS ONE* **2015**, *10*, e0120069. [CrossRef] [PubMed]
Colletti, M.; Tomao, L.; Galardi, A.; Paolini, A.; Di Paolo, V.; De Stefano, C.; Mascio, P.; Nazio, F.; Petrimi, S.; Castellano, A.; et al. Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells. *J. Extracell. Vesicles* 2020, 9, 174144. [CrossRef]

Hochheuser, C.; van Zogchel, L.M.J.; Kleijer, M.; Kuijck, C.; Tol, S.; van der Schout, C.E.; Voermans, C.; Tytgat, G.A.M.; Timmerman, I. The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells. *Cancers* 2020, 12, 3231. [CrossRef]

Morandi, F.; Marini, D.; Horenstein, A.L.; Corrias, M.V.; Malavasi, F. Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. *Oncoimmunology* 2019, 8, e1574198. [CrossRef]

Morandi, F.; Scaruffi, P.; Gallo, F.; Stigliani, S.; Moretti, S.; Bonassi, S.; Gambini, C.; Mazzocco, K.; Fardin, P.; Haupt, R.; et al. Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins. *PLoS ONE* 2012, 7, e29922. [CrossRef]

Anract, P.; Biau, D.; Boudou-Rouquette, P. Metastatic fractures of long limb bones. *Orthop. Traumatol. Surg. Res.* 2017, 103, S41–S51. [CrossRef] [PubMed]

Montilla-Soler, J.L.; Makanji, R. Skeletal Scintigraphy. *Cancer Control* 2017, 24, 137–146. [CrossRef]

Grootjans, W.; Seré, S.J.; Gomes, M.I.; Heijmen, L.; Bulten, B.F.; Mijnheere, E.P.; Hermoen, R.; van den Broek, W.J. Half-time bone scintigraphy in prostate and breast cancer patients. *Q. J. Nucl. Med. Mol. Imaging* 2018, 62, 303–312. [CrossRef] [PubMed]

Nakajima, K.; Edenbrandt, L.; Mizokami, A. Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer. *Int. J. Urol.* 2017, 24, 668–673. [CrossRef]

Schmidt, G.P.; Schoenberg, S.O.; Reiser, M.F.; Baur-Melnyk, A. Whole-body MR imaging of bone marrow. *Eur. J. Radiol.* 2005, 55, 33–40. [CrossRef]

Arita, Y.; Takahara, T.; Yoshida, S.; Kwee, T.C.; Yajima, S.; Ishii, C.; Ishii, R.; Okuda, S.; Jinzaki, M.; Fujiy, Y. Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging. *Investig. Radiol.* 2019, 54, 638–644. [CrossRef] [PubMed]

Beheshi, M. (18)F-Sodium Fluoride PET/CT and PET/MR Imaging of Bone and Joint Disorders. *PET Clin.* 2018, 13, 477–490. [CrossRef]

Chen, B.; Wei, P.; Macapinlac, H.A.; Lu, Y. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. *Nucl. Med. Commun.* 2019, 40, 940–946. [CrossRef]

Shimozuma, K.; Sonoo, H.; Fukunaga, M.; Ichihara, K.; Aoyama, T.; Tanaka, K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: A preliminary report. *Ipn. J. Clin. Oncol.* 1999, 29, 16–22. [CrossRef]

Chew, C.K.; Clarke, B.L. Biochemical Testing Relevant to Bone. *Endocrinol. Metab. Clin. N. Am.* 2017, 46, 649–667. [CrossRef] [PubMed]

Tanaka, A.; Katagiri, H.; Murata, H.; Wasa, J.; Miyagi, M.; Honda, Y.; Takahashi, M. Surgery for femoral metastases. *Bone Jt. J.* 2020, 102-B, 285–292. [CrossRef] [PubMed]

Saravanan-Bawan, S.; David, E.; Sahgal, A.; Chow, E. Palliation of bone metastases-exploring options beyond radiotherapy. *Ann. Palliat. Med.* 2019, 8, 168–177. [CrossRef] [PubMed]

Wenger, M. Vertebroplasty for metastasis. *Med. Oncol.* 2003, 20, 203–209. [CrossRef]

Zakaly, H.M.H.; Mostafa, M.Y.A.; Deryabina, D.; Zhukovsky, M. Comparative studies on the potential use of (177)Lu-based radiopharmaceuticals for the palliative therapy of bone metastases. *Int. J. Radiat. Biol.* 2020, 96, 779–789. [CrossRef]

Shore, N.D. Radium-223 dichloride for metastatic castration-resistant prostate cancer: The urologist’s perspective. *Urology* 2015, 85, 717–724. [CrossRef]

Park, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O’Sullivan, J.M.; Fossà, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N. Engl. J. Med.* 2013, 369, 213–223. [CrossRef]

Krýiakopoulos, C.E.; Chen, Y.H.; Carducci, M.A.; Liu, G.; Jarrard, D.F.; Hahn, N.M.; Shevrin, D.H.; Dreicer, R.; Hussain, M.; Eisenberger, M., et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. *J. Clin. Oncol.* 2018, 36, 1080–1087. [CrossRef]

Gdowski, A.S.; Ranjan, A.; Sarker, M.R.; Vishwanatha, J.K. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeleton lesions and pain. *nanomedicine* 2017, 12, 2083–2095. [CrossRef]

Miyoshi, Y.; Sakamoto, S.; Kawahara, T.; Uemora, K.; Yokomizo, Y.; Uemura, H. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Metastatic Prostate Cancer. *Cancer Med.* 2019, 10, 279–284. [CrossRef] [PubMed]

Kröger, N.; Achterrath, W.; Hegewisch-Becker, S.; Mross, K.; Zander, A.R. Current options in treatment of anthracycline-resistant breast cancer. *Cancer Treat. Rev.* 1999, 25, 279–291. [CrossRef] [PubMed]

Wang, J.; Zheng, R.; Wang, Z.; Yang, Y.; Wang, M.; Zou, W. Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes. *Med. Sci. Monit.* 2017, 23, 4657–4664. [CrossRef] [PubMed]

Amari, M.; Ishida, T.; Takeda, M.; Ohuchi, N. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. *Ipn. J. Clin. Oncol.* 2010, 40, 188–193. [CrossRef]
226. Smeland, S.; Bielack, S.S.; Whelan, J.; Bernstein, M.; Hogendoorn, P.; Krailo, M.D.; Gorlick, R.; Janeway, K.A.; Ingleby, F.C.; Anninga, J.; et al. Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *Eur. J. Cancer* 2019, 109, 36–50. [CrossRef]

227. Huang, M.; Lucas, K. Current therapeutic approaches in metastatic and recurrent ewing sarcoma. *Sarcoma* 2011, 2011, 863210. [CrossRef]

228. Khanna, N.; Pandey, A.; Bajpai, J. Metastatic Ewing’s Sarcoma: Revisiting the “Evidence on the Fence”. *Indian J. Med. Paediatr. Oncol.* 2017, 38, 173–181. [CrossRef]

229. Mercadante, S.; Fulfarro, F. Management of painful bone metastases. *Curr. Opin. Oncol.* 2007, 19, 308–314. [CrossRef]

230. Nanni, P.; Landuzzi, L.; Manara, M.C.; Righi, A.; Nicoletti, G.; Cristalli, C.; Pasello, M.; Parra, A.; Carrabotta, M.; Ferracin, M.; et al. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. *Sci. Rep.* 2019, 9, 12174. [CrossRef]

231. Braekevelt, N.; Wigerup, C.; Gisselsson, D.; Mohlin, S.; Merselius, M.; Beckman, S.; Jonson, T.; Borjesson, A.; Backman, T.; Tadeo, I.; et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. *Int. J. Cancer* 2015, 136, E252–E261. [CrossRef]

232. Rea, D.; Del Vecchio, V.; Palma, G.; Barbieri, A.; Falco, M.; Luciano, A.; De Biase, D.; Perdona, S.; Facchini, G.; Arra, C. Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. *BioMed Res. Int.* 2016, 2016, 9750795. [CrossRef] [PubMed]

233. Nemeth, J.A.; Harb, J.F.; Barroso, U., Jr; He, Z.; Grignon, D.J.; Cher, M.L. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. *Cancer Res.* 1999, 59, 1987–1993. [PubMed]

234. Schuster, J.; Zhang, J.J.; Longo, M. A novel human osteoblast-derived severe combined immunodeficiency mouse model of bone metastasis. *J. Neurosurg. Spine* 2006, 4, 388–391. [CrossRef]

235. Li, F.X.; Liu, J.J.; Xu, F.; Lin, X.; Zhong, J.Y.; Wu, F.; Yuan, L.Q. Role of tumor-derived exosomes in bone metastasis. *Oncol. Lett.* 2019, 18, 3935–3945. [CrossRef]

236. Johnson, R.W.; Finger, E.C.; Oclina, M.M.; Vilalta, M.; Aguiler, T.; Miao, Y.; Merkel, A.R.; Johnson, J.R.; Sterling, J.A.; Wu, J.Y.; et al. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. *Nat. Cell Biol.* 2016, 18, 1078–1089. [CrossRef] [PubMed]

237. Holen, I.; Lefley, D.V.; Francis, S.E.; Rennicks, S.; Bradbury, S.; Coleman, R.E.; Ottewell, P. IL-1 drives breast cancer growth and bone metastasis in vivo. *Oncotarget* 2016, 7, 75571–75584. [CrossRef]

238. Sawada, Y.; Kikugawa, T.; Iio, H.; Sakakibara, I.; Yoshida, S.; Ikedo, A.; Yanagihara, Y.; Saeki, N.; Gyorffy, B.; Kishida, T.; et al. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. *J. Bone Metastasis* 2020, 146, 1369–1382. [CrossRef] [PubMed]

239. Ganguly, S.S.; Hostetter, G.; Tang, L.; Frank, S.B.; Saboda, K.; Mehra, R.; Wang, L.; Li, X.; Keller, E.T.; Miranti, C.K. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. *Oncogene* 2020, 39, 204–218. [CrossRef] [PubMed]

240. Berish, R.B.; Ali, A.N.; Telmer, P.G.; Ronald, J.A.; Leong, H.S. Translational models of prostate cancer bone metastasis. *Nat. Rev. Urol.* 2018, 15, 403–421. [CrossRef] [PubMed]

241. D’Oronzo, S.; Coleman, R.; Brown, J.; Silvestris, F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. *J. Bone Oncol.* 2019, 15, 100025. [CrossRef]

242. Anastasiakis, A.D.; Polyzos, S.A.; Yavropoulou, M.P.; Makras, P. Combination and sequential treatment in women with postmenopausal osteoporosis. *Expert Opin. Pharmacother.* 2020, 21, 477–490. [CrossRef]

243. Marocco, C.; Zamitore, G.; Mocini, E.; Fornari, R.; Iolascon, G.; Cristalli, C.; Pasello, M.; Parra, A.; Carrabotta, M.; Ferracin, M.; et al. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. *Sci. Rep.* 2019, 9, 12174. [CrossRef]

244. Dirksen, U.; Koch, R.; Bhadri, V.; Brichard, B.; Butterfass-Bahloul, T.; Cyprova, S.; Gelderblom, H.; Hauser, P.; Havemann, L.; Hjorth, L.; et al. Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial. *J. Neurosurg. Spine* 2020, 1728. [CrossRef]

245. Sun, T.; Liu, Z.; Yang, Q. The role of ubiquitination and deubiquitination in cancer metabolism. *Cell Cycle* 2017, 16, 634–648. [CrossRef] [PubMed]

246. Li, S.; Chen, P.; Pei, Y.; Zheng, K.; Wang, W.; Qiu, E.; Zhang, X. Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial. *Med. Sci. Monit.* 2019, 25, 1429–1438. [CrossRef]

247. Dirksen, U.; Koch, R.; Bhadri, V.; Brichard, B.; Butterfass-Bahloul, T.; Cyprova, S.; Gelderblom, H.; Hauser, P.; Havemann, L.; Hjorth, L.; et al. Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial. *J. Clin. Oncol.* 2020, 38, 11523. [CrossRef]

248. Gallo, L.H.; Ko, J.; Donoghue, D.J. The importance of regulatory ubiquitination in cancer and metastasis. *Cell Cycle* 2017, 16, 634–648. [CrossRef] [PubMed]

249. Sun, T.; Liu, Z.; Yang, Q. The role of ubiquitination and deubiquitination in cancer metabolism. *Mol. Cancer* 2020, 19, 146. [CrossRef]

250. Toscani, D.; Cravito, L.; Giuliani, N. The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocysts. *Appl. Sci. 2021, 11*, 4642. [CrossRef]
251. Zhang, D.; Fan, R.; Lei, L.; Lei, L.; Wang, Y.; Lv, N.; Chen, P.; Williamson, R.A.; Wang, B.; Hu, J. Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21(Cip1) and p27(Kip1). J. Cell. Mol. Med. 2020, 24, 9428–9438. [CrossRef]

252. Zhang, D.; De Veirman, K.; Fan, R.; Jian, Q.; Zhang, Y.; Lei, L.; Evans, H.; Wang, Y.; Lei, L.; Wang, B.; et al. ER stress arm XBP1s plays a pivotal role in prostate cancer-induced bone formation. Stem Cell Res. Ther. 2020, 11, 516. [CrossRef]

253. Jones, M.D.; Liu, J.C.; Barthel, T.K.; Hussain, S.; Lovria, E.; Cheng, D.; Schoonmaker, J.A.; Mulay, S.; Ayers, D.C.; Boussx, M.L.; et al. A prostate cancer inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin. Cancer Res. 2010, 16, 4978–4989. [CrossRef]

254. Wang, Z.; Wang, J.; Li, X.; Xing, L.; Ding, Y.; Shi, P.; Zhang, Y.; Guo, S.; Shu, X.; Shan, B. Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurfl and Smurfl2. Int. J. Oncol. 2014, 45, 1469–1478. [CrossRef]

255. Xing, L.; Ebetino, F.H.; Boeckman, R.K., Jr.; Srinivasan, V.; Tao, J.; Sawyer, T.K.; Li, J.; Yao, Z.; Boyce, B.F. Targeting anti-cancer agents to bone using bisphosphonates. Bone 2020, 138, 115492. [CrossRef]

256. Russow, G.; Jahn, D.; Appelt, J.; Mordian, S.; Tsitsilonis, S.; Keller, J. Anabolic Therapies in Osteoporosis and Bone Regeneration. Int. J. Mol. Sci. 2018, 20, 83. [CrossRef] [PubMed]

257. Rothe, R.; Hauser, S.; Neuber, C.; Laube, M.; Schulze, S.; Rammelt, S.; Pietzsch, J. Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches. Pharmaceutics 2020, 12, 428. [CrossRef] [PubMed]

258. Romero-Moreno, R.; Curtis, K.J.; Coughlin, T.R.; Miranda-Vergara, M.C.; Dutta, S.; Natarajan, A.; Facchine, B.A.; Jackson, K.M.; Nystrom, L.; Li, J.; et al. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat. Commun. 2019, 10, 4403. [CrossRef]

259. Lee, S.; Burner, D.N.; Mendoza, T.R.; Muldong, M.T.; Arreola, C.; Wu, C.N.; Cacalano, N.A.; Kulidjian, A.A.; Kane, C.J.; Jamieson, D.A.; et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Cell Biol. 2017, 39, 1882–1894. [CrossRef] [PubMed]

260. Hao, S.; Ha, L.; Cheng, G.; Wan, Y.; Xia, Y.; Sonnoski, D.M.; Mastro, A.M.; Zheng, S.Y. A Spontaneous 3D Bone-On-a-Chip for Bone Metastasis Study of Breast Cancer Cells. Small 2018, 14, e1702787. [CrossRef]

261. Cui, H.; Esworthy, T.; Zhou, X.; Hany, S.; Glazer, R.I.; Li, R.; Zhang, L.G. Engineering a Novel 3D Printed Vascularized Tissue Model for Investigating Breast Cancer Metastasis to Bone. Adv. Healthc. Mater. 2020, 9, e1900924. [CrossRef]

262. Zhu, W.; Holmes, B.; Glazer, R.I.; Zhang, L.G. 3D Printed nanocomposite matrix for the study of breast cancer bone metastasis. Nanomedicine 2016, 12, 69–79. [CrossRef] [PubMed]

263. Aveic, S.; Janssen, S.; Nasehi, R.; Seidelmann, M.; Vogt, M.; Pantile, M.; Rutten, S.; Fischer, H. A 3D printed in vitro bone model for the assessment of molecular and cellular cues in metastatic neuroblastoma. Biomater. Sci. 2021, 9, 1716–1727. [CrossRef] [PubMed]

264. Yang, G.; Nowsheen, S.; Aziz, K.; Georgakilas, A.G. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol. Ther. 2013, 139, 392–404. [CrossRef] [PubMed]

265. Cristofanilli, M.; Turner, N.C.; Bondarenko, I.; Ro, J.; Im, S.A.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016, 17, 425–439. [CrossRef] [PubMed]

266. Smith, I.; Yardley, D.; Burris, H.; De Boer, R.; Amadori, D.; McNtynre, K.; Ejertsen, B.; Gnatt, M.; Jonat, W.; Pritchard, K.I.; et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone-Receptor-Positive, Node-Negative Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J. Clin. Oncol. 2017, 35, 1041–1048. [CrossRef]

267. Tao, J.; Sawyer, T.K.; Li, J.; Yao, Z.; Boyce, B.F. Targeting anti-cancer agents to bone using bisphosphonates. Bone 2020, 138, 115492. [CrossRef]

268. Krebs, A.M.; Mitschke, J.; Lasierra Losada, M.; Schmalhofer, O.; Boerries, M.; Busch, H.; Boettcher, M.; Mougiakakos, D.; Reichardt, W.; Bronsert, P.; et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 2017, 19, 518–529. [CrossRef] [PubMed]

269. Diepenbruck, M.; Tiede, S.; Saxena, M.; Ivanek, R.; Kalathur, R.K.R.; Lüönd, F.; Meyer-Schaller, N.; Christofori, G. miR-1199-5p and Zeb1 function in a double-negative feedback loop potentially coordinating EMT and tumour metastasis. Nat. Commun. 2017, 8, 1168. [CrossRef] [PubMed]
274. Muz, B.; Abdelghafar, A.; Markovic, M.; Yavner, J.; Melam, A.; Salama, N.N.; Azab, A.K. Targeting E-selectin to Tackle Cancer Using Uproleselan. *Cancers* 2021, 13, 335. [CrossRef]

275. Esposito, M.; Kang, Y. Targeting tumor-stroma interactions in bone metastasis. *Pharmacol. Ther.* 2014, 141, 222–233. [CrossRef]

276. Heckmann, D.; Maier, F.; Laufs, S.; Wenz, F.; Zeller, W.J.; Fruehauf, S.; Allgayer, H. CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells. *Transl. Oncol.* 2015, 6, 124–132. [CrossRef]

277. Shiozawa, Y.; Federsen, E.A.; Patel, L.R.; Ziegler, A.M.; Havens, A.M.; Jung, Y.; Wang, J.; Zalucha, S.; Loberg, R.D.; Pienta, K.J.; et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. *Neoplasia* 2010, 12, 116–127. [CrossRef]

278. Zhang, Y.X.; Knyazev, P.G.; Cheburkin, Y.V.; Sharma, K.; Knyazev, Y.P.; Orfi, L.; Szabadkai, I.; Daub, H.; Kéri, G.; Ullrich, A. AXL is a potential target for therapeutic intervention in breast cancer progression. *Cancer Res.* 2008, 68, 1905–1915. [CrossRef]

279. Kolb, A.D.; Shupp, A.B.; Mukhopadhyay, D.; Marini, F.C.; Bussard, K.M. Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. *Breast Cancer Res.* 2019, 21, 31. [CrossRef]

280. Xiang, L.; Gilkes, D.M. The Contribution of the Immune System in Bone Metastasis Pathogenesis. *Int. J. Mol. Sci.* 2019, 20, 999. [CrossRef]

281. Kahkonen, T.E.; Halleen, J.M.; Bernoulli, J. Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis. *Cells* 2021, 10, 1529. [CrossRef] [PubMed]

282. Tsukasaki, M.; Takayanagi, H. Osteoimmunology: Evolving concepts in bone-immune interactions in health and disease. *Nat. Rev. Immunol.* 2019, 19, 626–642. [CrossRef] [PubMed]

283. Walsh, M.C.; Takegahara, N.; Kim, H.; Choi, Y. Updating osteoimmunology: Regulation of bone cells by innate and adaptive immunity. *Nat. Rev. Rheumatol.* 2018, 14, 146–156. [CrossRef]

284. Mendoza-Reinoso, V.; McCauley, L.K.; Fournier, P.G.J. Contribution of Macrophages and T Cells in Skeletal Metastasis. *Cancers* 2020, 12, 1014. [CrossRef] [PubMed]

285. Ardura, J.A.; Rackov, G.; Izquierdo, E.; Alonso, V.; Gortazar, A.R.; Escribese, M.M. Targeting Macrophages: Friends or Foes in Disease? *Front. Pharmacol.* 2019, 10, 1255. [CrossRef] [PubMed]

286. Sawant, A.; Hensel, J.A.; Chanda, D.; Harris, B.A.; Siegal, G.P.; Maheshwari, A.; Ponnazhagan, S. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. *J. Immunol.* 2012, 189, 4258–4265. [CrossRef]

287. Wu, M.Y.; Li, C.J.; Yang, G.T.; Cheng, Y.L.; Tsai, A.P.; Hou, Y.T.; Ho, Y.C.; Hou, M.F.; Chu, P.Y. Molecular Regulation of Bone Metastasis Pathogenesis. *Cells* 2018, 7, 1432. [CrossRef] [PubMed]

288. Zhao, E.; Wang, L.; Dai, J.; Kryczek, I.; Wei, S.; Vatan, L.; Altuwaijri, S.; Sparwasser, T.; Wang, G.; Keller, E.T.; et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. *Oncoimmunology* 2012, 1, 152–161. [CrossRef]

289. Dahlberg, C.I.; Sarhan, D.; Chrobok, M.; Duru, A.D.; Alici, E. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. *Front. Immunol.* 2015, 6, 605. [CrossRef]

290. Romee, R.; Leong, J.W.; Fehniger, T.A. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. *Scientific* 2014, 2014, 205796. [CrossRef]

291. Kitamura, T.; Qian, B.Z.; Soong, D.; Cassette, L.; Noy, R.; Sugano, G.; Kato, Y.; Li, J.; Pollard, J.W. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. *J. Exp. Med.* 2015, 212, 1043–1059. [CrossRef] [PubMed]

292. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumor-associated macrophages as treatment targets in oncology. *Nat. Rev. Clin. Oncol.* 2017, 14, 399–416. [CrossRef] [PubMed]

293. Cannarie, M.A.; Weisser, M.; Jacob, W.; Jegg, A.M.; Ries, C.H.; Ruttinger, D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. *J. Immunother. Cancer* 2017, 5, 53. [CrossRef] [PubMed]

294. Guerriero, J.L. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. *Trends Mol. Med.* 2018, 24, 472–489. [CrossRef]

295. Dong, R.; Gong, Y.; Meng, W.; Yuan, M.; Zhu, H.; Ying, M.; He, Q.; Cao, J.; Yang, B. The involvement of M2 macrophage polarization inhibition in fenretinide-mediated chemopreventive effects on colon cancer. *Cancer Lett.* 2017, 388, 43–53. [CrossRef]

296. Edwards, J.P.; Emens, L.A. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. *Int. Immunopharmacol.* 2010, 10, 1220–1228. [CrossRef]

297. Muller, P.; Martin, K.; Theurich, S.; von Bergwelt-Baildon, M.; Zippelius, A. Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. *Oncoimmunology* 2014, 3, e95460. [CrossRef] [PubMed]

298. Luo, G.; He, Y.; Zhao, Q.; Yu, X. Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis. *Recent Pat. Anticancer Drug Discov.* 2017, 12, 221–233. [CrossRef]

299. Renard, S.I.; Dale, D.C.; Donohue, J.F.; Kannies, F.; Magnussen, H.; Sutherland, E.R.; Watz, H.; Lu, S.; Stryszak, P.; Rosenberg, E.; et al. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 2015, 191, 1001–1011. [CrossRef]

300. Benevides, L.; da Fonseca, D.M.; Donate, P.B.; Tiezzi, D.G.; De Carvalho, D.D.; de Andrade, J.M.; Martins, G.A.; Silva, J.S. IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment. *Cancer Res.* 2015, 75, 3788–3799. [CrossRef]
301. Fridlender, Z.G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G.S.; Albelda, S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. *Cancer Cell* 2009, 16, 183–194. [CrossRef]

302. Gomez-Aleza, C.; Nguyen, B.; Yoldi, G.; Ciscar, M.; Barranco, A.; Hernandez-Jimenez, E.; Maetens, M.; Salgado, R.; Zafeiroglou, M.; Pellegrini, P.; et al. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. *Nat. Commun.* 2020, 11, 6335. [CrossRef]

303. Jiao, S.; Subudhi, S.K.; Aparicio, A.; Ge, Z.; Guan, B.; Miura, Y.; Sharma, P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. *Cell* 2019, 179, 1177–1190.e13. [CrossRef]

304. Moseley, K.F.; Naidoo, J.; Bingham, C.O.; Carducci, M.A.; Forde, P.M.; Gibney, G.T.; Lipson, E.J.; Shah, A.A.; Sharifman, W.H.; Cappelli, L.C. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series. *J. Immunother. Cancer* 2018, 6, 104. [CrossRef] [PubMed]

305. Hilal, T.; Bansal, P.; Kelemen, K.; Slack, J. Nivolumab-associated bone marrow necrosis. *Ann. Oncol.* 2018, 29, 513–514. [CrossRef]

306. Pillai, S.G.; Li, S.; Siddappa, C.M.; Ellis, M.J.; Watson, M.A.; Aft, R. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model. *Breast Cancer Res.* 2018, 20, 2. [CrossRef] [PubMed]

307. La Manna, F.; De Menna, M.; Patel, N.; Karkampouna, S.; De Filippo, M.R.; Klima, I.; Kloen, P.; Beimers, L.; Thalmann, G.N.; Pelger, R.C.M.; et al. Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. *Front. Oncol.* 2020, 10, 1012. [CrossRef] [PubMed]

308. Karkampouna, S.; De Filippo, M.R.; Ng, C.K.Y.; Klima, I.; Zoni, E.; Spahn, M.; Stein, F.; Haberkant, P.; Thalmann, G.N.; Kruthof-de Julio, M. Stroma Transcriptomic and Proteomic Profile of Prostate Cancer Metastasis Xenograft Models Reveals Prognostic Value of Stroma Signatures. *Cancers* 2020, 12, 3786. [CrossRef]

309. Lefley, D.; Howard, F.; Arshad, F.; Bradbury, S.; Brown, H.; Tulotta, C.; Eyre, R.; Alferez, D.; Wilkinson, J.M.; Holen, I.; et al. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. *Breast Cancer Res.* 2019, 21, 130. [CrossRef]

310. Katti, K.S.; Jasuja, H.; Kar, S.; Katti, D.R. Nanostructured Biomaterials for In Vitro Models of Bone Metastasis Cancer. *Curr. Opin. Biomed. Eng.* 2021, 17, 100254. [CrossRef]

311. Hughes, A.M.; Kolb, A.D.; Shupp, A.B.; Shine, K.M.; Bussard, K.M. Printing the Pathway Forward in Bone Metastatic Cancer Research: Applications of 3D Engineered Models and Bioprinted Scaffolds to Recapitulate the Bone-Tumor Niche. *Cancers* 2021, 13, 507. [CrossRef] [PubMed]